Soldano Ferrone

Q: What Schools Are Affiliated With Soldano Ferrone

Soldano Ferrone is affiliated with the following schools: New York Medical College, University of Tokyo, Icahn School of Medicine at Mount Sinai, University of Basel, University of California, San Francisco, Massachusetts General Hospital, Duke University, University of Trieste, University of Hawaiʻi at Mānoa, Stanford University, Johns Hopkins University, University of Pittsburgh, Leiden University, Harvard University

Soldano Ferrone's AcademicInfluence.com Rankings

Soldano Ferrone

Biology

#3324

World Rank

#5099

Historical Rank

#1360

USA Rank

Immunology

#133

World Rank

#140

Historical Rank

#45

USA Rank

biology Degrees

Download Badge

Biology

Soldano Ferrone's Degrees

PhD Immunology Stanford University

Why Is Soldano Ferrone Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Soldano Ferrone's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. (2000) (1220)
Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. (2002) (547)
Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. (1995) (533)
Antigen-processing machinery breakdown and tumor growth. (2000) (486)
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. (2009) (407)
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. (2017) (397)
Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2-amino ethylisothiouronium bromide. (1975) (385)
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. (1999) (382)
Immunotherapy of cancer in 2012 (2012) (367)
Soluble HLA‐A,‐B,‐C and ‐G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation (2003) (359)
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance (2008) (345)
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. (2009) (328)
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing (2013) (325)
Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. (1991) (312)
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. (2010) (303)
Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. (1990) (296)
Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma Patients (2010) (295)
Distribution and molecular characterization of a cell‐surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies (1981) (291)
Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. (1992) (276)
HLA class I antigen abnormalities and immune escape by malignant cells. (2002) (270)
Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. (1999) (264)
Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients (2013) (263)
Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. (2004) (256)
Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. (1994) (253)
Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. (1989) (250)
Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outcome (2005) (248)
HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? (2005) (247)
TAP off--tumors on. (1997) (233)
EXPRESSION OF Ia‐LIKE ANTIGENS IN NORMAL HUMAN NONLYMPHOID TISSUES (1981) (232)
Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. (2019) (231)
CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. (2015) (212)
Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. (2001) (211)
Tumors as elusive targets of T-cell-based active immunotherapy. (2003) (210)
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. (1998) (207)
Re.: Purification of IgG monoclonal antibody by caprylic acid precipitation. (1983) (204)
Immune Escape Associated with Functional Defects in Antigen-Processing Machinery in Head and Neck Cancer (2006) (196)
Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy (2017) (188)
Detection of soluble HLA-G molecules in plasma and amniotic fluid. (1999) (187)
Chemotherapy‐induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death (2013) (186)
Soluble HLA-G: Are they clinically relevant? (2007) (184)
Human Leukocyte Antigen and Antigen Processing Machinery Component Defects in Astrocytic Tumors (2005) (181)
Lost in Translation: Obstacles to Translational Medicine (2004) (180)
Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. (2004) (180)
HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. (1998) (177)
Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma (2007) (176)
Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. (1984) (176)
Immunoaffinity-based isolation of melanoma cell-derived exosomes from plasma of patients with melanoma (2018) (176)
Isolation of human T and B lymphocytes by rosette formation with 2-aminoethylisothiquronium bromide (AET) -treated sheep red blood cells with monkey red blood cells. (1976) (172)
Programmed Cell Death Ligand 1 Expression in Osteosarcoma (2014) (171)
HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. (2006) (171)
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells (2009) (167)
Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. (1984) (167)
Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. (2005) (165)
β2-Microglobulin-Free HLA Class I Heavy Chain Epitope Mimicry by Monoclonal Antibody HC-10-Specific Peptide1 (2003) (164)
Where have all the T cells gone? Mechanisms of immune evasion by tumors. (1999) (163)
PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients1 (2009) (162)
Clinical Significance of αvβ3 Integrin and Intercellular Adhesion Molecule-1 Expression in Cutaneous Malignant Melanoma Lesions (1997) (160)
Soluble human leukocyte antigen–G serum level is elevated in melanoma patients and is further increased by interferon‐α immunotherapy (2001) (160)
Monoclonal antibodies for cancer immunotherapy (2009) (160)
Role of Antigen-Processing Machinery in the In Vitro Resistance of Squamous Cell Carcinoma of the Head and Neck Cells to Recognition by CTL1 (2006) (155)
PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma (2015) (155)
Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. (1988) (154)
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. (2010) (153)
Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms (2004) (151)
Serologic and immunochemical characterization of the specificity of four monoclonal antibodies to distinct antigenic determinants expressed on subpopulations of human Ia-like antigens. (1981) (149)
Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. (2005) (148)
Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. (1983) (146)
HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma (2008) (145)
Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells. (1984) (145)
MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma (2004) (142)
Targeting ALDHbright Human Carcinoma–Initiating Cells with ALDH1A1-Specific CD8+ T Cells (2011) (142)
Immunogenicity of Human Mesenchymal Stem Cells in HLA‐Class I‐Restricted T‐Cell Responses Against Viral or Tumor‐Associated Antigens (2008) (140)
CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma (2011) (139)
Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells (2011) (138)
Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. (1989) (136)
HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. (2000) (136)
Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vγ9/Vδ2 T cells in tumor immunity (1997) (135)
Preliminary classification criteria for the cryoglobulinaemic vasculitis (2011) (134)
Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity (2011) (133)
Structural and functional analysis of monomorphic determinants recognized by monoclonal antibodies reacting with the HLA class I alpha 3 domain. (1992) (133)
Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? (2011) (130)
Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy (2018) (129)
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck (2010) (128)
Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. (1983) (127)
Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation (2006) (126)
DR (Ia-like) antigens on human melanoma cells. Serological detection and immunochemical characterization (1979) (126)
HLA class I antigen loss, tumor immune escape and immune selection. (2002) (124)
Purification of human immunoglobulins by sequential precipitation with caprylic acid and ammonium sulphate. (1990) (124)
Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression (2014) (123)
MHC antigens in human melanomas. (1991) (122)
Murine Ia and human DR antigens: homology of amino-terminal sequences. (1978) (122)
HETEROGENEOUS DISTRIBUTION OF THE DETERMINANTS DEFINED BY MONOCLONAL ANTIBODIES ON HLA‐A AND B ANTIGENS BEARING MOLECULES (1982) (119)
Different Requirements for Signal Transducer and Activator of Transcription 1α and Interferon Regulatory Factor 1 in the Regulation of Low Molecular Mass Polypeptide 2 and Transporter Associated with Antigen Processing 1 Gene Expression* (1998) (118)
Modulation of Signal Transducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFNα2b (2007) (118)
HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. (2005) (117)
Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. (2003) (117)
Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. (2000) (117)
Purification of immunologically functional subsets of human Ia-like antigens on a monoclonal antibody (Q5/13) immunoadsorbent. (1980) (116)
Serum HLA class I antigens: markers and modulators of an immune response? (1995) (116)
Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions. (1986) (116)
Activation of toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors (2008) (115)
Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. (1993) (115)
Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? (2004) (115)
Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells (2020) (114)
Immune selective pressure and HLA class I antigen defects in malignant lesions (2006) (114)
Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. (2005) (114)
Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. (2007) (112)
Characterization of monoclonal antibodies to human melanoma-associated antigens. (1981) (112)
Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40S to human melanoma cells. (1981) (112)
Selective Histocompatibility Leukocyte Antigen (Hla)-A2 Loss Caused by Aberrant Pre-mRNA Splicing in 624mel28 Melanoma Cells (1999) (111)
CSPG4 in cancer: multiple roles. (2010) (108)
Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells (2014) (107)
A 94,000-dalton glycoprotein expressed by human melanoma and carcinoma cells. (1982) (106)
HLA-G and MIC expression in tumors and their role in anti-tumor immunity. (2003) (106)
Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? (2004) (106)
Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications (2005) (105)
Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies. (1989) (105)
Immune Selection of Hot-Spot β2-Microglobulin Gene Mutations, HLA-A2 Allospecificity Loss, and Antigen-Processing Machinery Component Down-Regulation in Melanoma Cells Derived from Recurrent Metastases following Immunotherapy1 (2005) (105)
Characterization of a monoclonal antibody-defined human melanoma-associated antigen susceptible to induction by immune interferon. (1987) (104)
NK cells and T cells cooperate during the clinical course of colorectal cancer (2014) (104)
Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. (2003) (104)
Enrichment of CD56dimKIR+CD57+ highly cytotoxic NK cells in tumor infiltrated lymph nodes of melanoma patients (2014) (104)
Association of HLA class I and class II antigen expression and mortality in uveal melanoma. (2001) (103)
Diffusion-weighted MRI in evaluating liver fibrosis: a feasibility study in cirrhotic patients (2007) (102)
Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. (1993) (102)
Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. (1993) (101)
Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. (2008) (100)
HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression (2007) (99)
Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer (2010) (99)
Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level (2012) (99)
Functional and clinical relevance of chondroitin sulfate proteoglycan 4. (2010) (98)
Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients (2016) (98)
Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4 (2014) (96)
Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. (2009) (95)
Ipilimumab in the treatment of metastatic melanoma: management of adverse events (2014) (95)
The complex role of B7 molecules in tumor immunology. (2008) (95)
Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma (2011) (93)
Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? (2006) (93)
Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. (1994) (93)
HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. (2014) (92)
Immunoregulatory properties of CD44+ cancer stem‐like cells in squamous cell carcinoma of the head and neck (2011) (92)
Expression and prognostic significance of prothymosin-α and ERp57 in human gastric cancer (2007) (91)
Sequential Immune Escape and Shifting of T Cell Responses in a Long-Term Survivor of Melanoma 1 (2005) (90)
Blocking the formation of radiation–induced breast cancer stem cells (2014) (90)
Differential role of distinct determinants of intercellular adhesion molecule-1 in immunologic phenomena. (1989) (90)
Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. (2003) (89)
Biologic and chemical characterization of HLA antigens in human serum. (1977) (88)
Tumor microenvironment and immune escape. (2007) (87)
Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma (2017) (87)
B7-H3: An Attractive Target for Antibody-based Immunotherapy (2020) (87)
Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. (1993) (87)
Chordoma and chondrosarcoma gene profile: implications for immunotherapy (2009) (86)
Antigen-Processing Machinery in Human Dendritic Cells: Up-Regulation by Maturation and Down-Regulation by Tumor Cells1 (2004) (86)
Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes (2011) (85)
Expression of HLA class I antigens on hepatocytes in liver disease. (1986) (85)
Common antigenic determinants on human melanoma, glioma, neuroblastoma, and sarcoma cells defined with monoclonal antibodies. (1981) (84)
Mechanisms of immune evasion of human neuroblastoma. (2005) (83)
Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an In vitro melanoma model (1999) (83)
Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. (1997) (82)
Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy (2017) (82)
Level of a membrane-bound high-molecular-weight melanoma-associated antigen and a cytoplasmic melanoma-associated antigen in surgically removed tissues and in sera from patients with melanoma. (1984) (82)
CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer (2016) (82)
B peripheral lymphocytes express more HLA antigens than T peripheral lymphocytes. (1978) (81)
Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. (2006) (81)
Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. (2005) (80)
CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma (2012) (80)
The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. (2005) (80)
Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens. (1984) (80)
Differential effect of interferon on the expression of tumor-associated antigens and histocompatibility antigens on human melanoma cells: relationship to susceptibility to immune lysis mediated by monoclonal antibodies. (1981) (80)
Immunotherapy of Malignant Disease with Tumor Antigen–Specific Monoclonal Antibodies (2009) (79)
Isolation of human T lymphocytes: comparison between nylon wool filtration and rosetting with neuraminidase (VCN) and 2-aminoethylisothiouronium bromide (AET)-treated sheep red blood cells (SRBC). (1980) (79)
Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. (2008) (79)
B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres (2019) (78)
HLA class I defects in malignant lesions: what have we learned? (2003) (78)
TAP1 down‐regulation in primary melanoma lesions: An independent marker of poor prognosis (2001) (78)
Structural studies of murine I-E and human DR antigens. (1979) (77)
Tissue distribution, molecular profile, and shedding of a cytoplasmic antigen identified by the monoclonal antibody 465.12S to human melanoma cells. (1982) (76)
Restoration by IL-15 of MHC Class I Antigen-Processing Machinery in Human Dendritic Cells Inhibited by Tumor-Derived Gangliosides1 (2005) (76)
T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo (2013) (74)
A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. (2012) (73)
Monoclonal antibodies to HLA-A,B, and Ia-like antigens inhibit colony formation by human myeloid progenitor cells. (1980) (73)
A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. (2010) (73)
Expression of intercellular adhesion molecule-1 (CD54) on hematopoietic progenitors. (1991) (73)
HLA antigens in colorectal tumours--low expression of HLA class I antigens in mucinous colorectal carcinomas. (1987) (73)
mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. (2009) (72)
Expression of Ia-like and HLA-A,B antigens on human multipotential hematopoietic progenitor cells. (1982) (72)
Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. (2010) (71)
Report on the second new world B-cell workshop. (1977) (71)
Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. (1986) (71)
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells (2016) (70)
Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. (1995) (70)
Regulatory role of a monomorphic determinant of HLA Class I antigens in T cell proliferation. (1985) (69)
Ia-like antigens on human T lymphocytes: relationship to other surface markers, role in mixed lymphocyte reactions, and structural profile. (1980) (69)
Human leukocyte antigen (HLA) class I defects in head and neck cancer (2005) (68)
Polyclonality of BRAF mutations in acquired melanocytic nevi. (2009) (67)
Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. (1993) (67)
Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. (1991) (67)
Phase I Study of Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (2006) (67)
LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma (2013) (67)
Modulation by interferons of HLA antigen, high-molecular-weight melanoma associated antigen, and intercellular adhesion molecule 1 expression by cultured melanoma cells with different metastatic potential. (1989) (67)
Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions. (1991) (66)
Mechanisms of tumor evasion. (2005) (66)
The role of cancer stem cells in the modulation of anti-tumor immune responses. (2018) (66)
DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. (2005) (66)
HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse (2001) (65)
EQUINE T LYMPHOCYTES EXPRESS MHC CLASS II ANTIGENS (1986) (64)
A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. (2005) (64)
STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients (2015) (63)
SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells (2013) (63)
Melanoma cells inhibit NK cell functions. (2012) (63)
Mitochondrial miRNA Determines Chemoresistance by Reprogramming Metabolism and Regulating Mitochondrial Transcription. (2019) (63)
Characterization of WiDr: A human colon carcinoma cell line (1979) (62)
A rapid method for direct HL-A typing of cultured lymphoid cells. (1971) (62)
THE ACTION OF TWO SULFHYDRYL COMPOUNDS ON NORMAL HUMAN RED CELLS. RELATIONSHIP TO RED CELLS OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA. (1965) (61)
Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy (2012) (61)
Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma. (1985) (61)
Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. (2011) (60)
Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves beta(2)-integrin-mediated interaction. (2009) (60)
HLA-B*3501-peptide interactions: role of anchor residues of peptides in their binding to HLA-B*3501 molecules. (1994) (60)
Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues. (1993) (60)
HLA-DR antigen-negative acute myeloid leukemia (2003) (60)
Defective HLA class I antigen processing machinery in cancer (2018) (60)
Vitiligo autoantibodies are effective against melanoma (1993) (60)
The Humoral Theory of Transplantation (2017) (59)
Immunochemical and functional analysis of HLA class II antigens induced by recombinant immune interferon on normal epidermal melanocytes. (1987) (59)
Expression of antigen processing and presenting molecules in brain metastasis of breast cancer (2012) (59)
IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma (2020) (58)
Structural Relatedness of Distinct Determinants Recognized by Monoclonal Antibody TP25.99 on β2-Microglobulin-Associated and β2-Microglobulin-Free HLA Class I Heavy Chains1 (2000) (58)
PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation (2014) (58)
WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? (2007) (58)
HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance (2017) (57)
Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-γ treatments: results from a multicentric study. (2013) (57)
Association of IFN-γ Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines (2011) (57)
Analysis of the interaction between a human high molecular weight melanoma-associated antigen and the monoclonal antibodies to three distinct antigenic determinants. (1985) (57)
Evolution of the MHC: antigenicity and unusual tissue distribution of Xenopus (frog) class II molecules. (1990) (57)
Tumor-associated antigens in spent medium of human melanoma cells: immunochemical characterization with xenoantisera. (1981) (56)
Defective Human Leukocyte Antigen Class I-associated Antigen Presentation Caused by a Novel β2-Microglobulin Loss-of-function in Melanoma Cells* (2006) (56)
Structural polymorphism of human DR antigens (1979) (56)
A Single-nucleotide Deletion Leads to Rapid Degradation ofTAP-1 mRNA in a Melanoma Cell Line* (2003) (55)
Heterogeneity of HLA-A,B, Ia-like, and Melanom Expression by Human Melanoma Cell Lines Analyzed with Monoclonal Antibodies and Flow Cytometry (1982) (55)
Evaluation of two sources of soluble HL‐A antigens: platelets and serum (1974) (55)
Multiple Structural and Epigenetic Defects in the Human Leukocyte Antigen Class I Antigen Presentation Pathway in a Recurrent Metastatic Melanoma Following Immunotherapy* (2015) (55)
Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas (2010) (55)
Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. (2007) (54)
Immunogenicity of Human Neuroblastoma (2004) (54)
Future perspectives in melanoma research (2016) (54)
Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies (2010) (54)
Detection of human histocompatibility (HLA) antigens with an indirect rosette microassay. (1979) (54)
CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA (2014) (54)
Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. (2006) (54)
Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes (2010) (53)
Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs) (2019) (53)
Double determinant immunoassay to measure a human high-molecular-weight melanoma-associated antigen. (1983) (53)
Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms. (2003) (53)
Immunochemical analysis of the modulation of human melanoma-associated antigens by DNA recombinant immune interferon. (1985) (53)
The lymphocytotoxic reaction: the mechanism of rabbit complement action. (1971) (52)
Gene products of the HLA-D region in normal and malignant tissues of nonlymphoid origin. (1986) (52)
FINE SPECIFICITY AND IDIOTYPE DIVERSITY OF THE MURINE ANTI‐HLA‐A2, A28 MONOCLONAL ANTIBODIES CR11–351 AND KS1 (1988) (52)
A Simple Microabsorption Technique for HL-A Typing 1 (1972) (51)
Vaccination with a Human High Molecular Weight Melanoma-Associated Antigen Mimotope Induces a Humoral Response Inhibiting Melanoma Cell Growth In Vitro1 (2005) (51)
HLA-G in melanoma: can the current controversies be solved? (2003) (51)
Expression of histocompatibility (HLA) antigens on tumor cells and normal cells from patients with melanoma (1977) (51)
Human DR (Ia-like) antigens: biological and molecular profile. (1978) (51)
Mesangial expression of intercellular adhesion molecule-1 in primary glomerulosclerosis. (1992) (50)
NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy (2007) (50)
Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells. (2016) (49)
CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma (2021) (49)
The monoclonal antibody CR11-351 discriminates HLA-A2 variants identified by T cells (2004) (49)
Long Noncoding RNA MPRL Promotes Mitochondrial Fission and Cisplatin Chemosensitivity via Disruption of Pre-miRNA Processing (2019) (49)
Signal transduction in lymphocyte activation through crosslinking of HLA class I molecules. (1989) (49)
Evaluation of C3 receptors on lymphoid cells with different complement sources. (1974) (49)
Cell cycle and the differential expression of HLA-A,B and HLA-DR antigens on human B lymphoid cells. (1980) (48)
Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells? (1998) (48)
Production and characterization of DR xenoantisera: use for detection of serum DR antigens. (1979) (48)
Association of high molecular weight melanoma-associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis. (1993) (48)
Association of immunoescape mechanisms with Epstein‐Barr virus infection in nasopharyngeal carcinoma (2007) (48)
Modified flow cytometry and cell-ELISA methodology to detect HLA class I antigen processing machinery components in cytoplasm and endoplasmic reticulum. (2003) (48)
How much longer will tumour cells fool the immune system? (2000) (48)
Immunoreactivity and biodistribution of indium-111-labeled monoclonal antibody to a human high molecular weight-melanoma associated antigen. (1985) (47)
Limited diversity of human scFv fragments isolated by panning a synthetic phage-display scFv library with cultured human melanoma cells. (1998) (47)
HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis? (2004) (47)
Breast cancer cells expressing stem cell markers CD44+ CD24lo are eliminated by Numb-1 peptide-activated T cells (2009) (47)
Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients (2015) (46)
Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29. (1998) (46)
Rosette formation of human lymphoid cells with monkey red blood cells. (1975) (46)
Molecular and Functional Profiles of Exosomes From HPV(+) and HPV(−) Head and Neck Cancer Cell Lines (2018) (46)
Antigenic heterogeneity of skin tumors of nonmelanocyte origin: analysis with monoclonal antibodies to tumor-associated antigens and to histocompatibility antigens. (1983) (46)
Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells (2009) (45)
Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies. (1989) (45)
Increased level of serum HLA class I antigens in HIV infection. Correlation with disease progression. (1994) (45)
T lymphocyte-mediated cytotoxicity against autologous EBV-genome-bearing B cells. (1981) (44)
Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression. (1996) (44)
A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. (2017) (44)
Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice (2008) (44)
Molecular mimicry of phage displayed peptides mimicking GD3 ganglioside (1999) (43)
Pathologic and gene expression features of metastatic melanomas to the brain (2013) (43)
Differential expression of HLA-DR, DQ, and DP antigens in primary and metastatic melanoma. (1988) (43)
NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus (2010) (43)
Monoclonal antibodies to human melanoma-associated antigens. (1980) (43)
Characterization of human anti-high molecular weight-melanoma-associated antigen single-chain Fv fragments isolated from a phage display antibody library. (1998) (43)
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 (2013) (42)
Soluble HLA antigens: new roles and uses. (1997) (42)
VARIATION IN SUSCEPTIBILITY OF A HUMAN LYMPHOID CELL LINE TO IMMUNE LYSIS DURING THE CELL CYCLE (1974) (42)
Immunogenicity of human melanoma-associated antigens defined by murine monoclonal antibodies in allogeneic and xenogeneic hosts. (1987) (42)
B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models. (2017) (42)
Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells (2006) (41)
Expression of HL-A antigens in synchronized cultures of human lymphocytes. (1972) (41)
Imaging of human melanoma xenografts in nude mice with a radiolabeled monoclonal antibody. (1982) (41)
Characterization of Ia antigens in mouse serum. (1976) (40)
Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram (2020) (40)
For Breast Cancer Prognosis, Immunoglobulin Kappa Chain Surfaces to the Top (2012) (40)
IMMUNOGENICITY OF SERUM HLA ANTIGENS IN ALLOGENEIC COMBINATIONS (1982) (40)
Targeting Melanoma Cells with Human High Molecular Weight-Melanoma Associated Antigen-Specific Antibodies Elicited by a Peptide Mimotope: Functional Effects (2006) (40)
Presensitization detected by sensitive crossmatch tests. (1973) (39)
FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance (2017) (39)
Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross‐presenting function (2008) (39)
Human high molecular weight-melanoma associated antigen mimicry by an anti-idiotypic antibody: characterization of the immunogenicity and the immune response to the mouse monoclonal antibody IMel-1. (1991) (39)
Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2′-deoxycytidine (2005) (39)
Uptake of methotrexate linked to polyclonal and monoclonal antimelanoma antibodies by a human melanoma cell line. (1985) (39)
Profile of intercellular adhesion molecule-1 (ICAM-1) synthesized by human melanoma cell lines. (1988) (38)
NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo (2020) (38)
Higher cytolytic efficiency of an IgG2 alpha than of an IgG1 monoclonal antibody reacting with the same (or spatially close) determinant on a human high-molecular-weight melanoma-associated antigen. (1982) (38)
Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma (2003) (38)
Analysis with monoclonal antibodies of the molecular and cellular heterogeneity of human high molecular weight melanoma associated antigen. (1987) (38)
Ia-like antigens on freshly explanted human melanoma. (1981) (38)
Summary report from the first international workshop on soluble HLA antigens. Paris, August 1992. (1993) (38)
Purification and immunologic evaluation of human melnoma-associated antigens. (1978) (38)
Human high molecular weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody MK2-23. Characterization of the immunogenicity in syngeneic hosts. (1991) (38)
Immunotherapy of Melanoma Targeting Human High Molecular Weight Melanoma‐Associated Antigen: Potential Role of Nonimmunological Mechanisms (2004) (37)
Expression of C4 on human lymphoid cells and possible involvement in immune recognition phenomena. (1976) (37)
Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. (2005) (37)
Expression of Ia-like antigens on the vasculature of human kidney. (1981) (37)
Down-regulation of Human Leukocyte Antigen class I heavy chain in tumors is associated with a poor prognosis in advanced esophageal cancer patients (2011) (37)
T-cell receptors and ICAM-1 expression in renal allografts during rejection (1991) (36)
Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4‐antigen electrovaccination (2017) (36)
Lymphocytotoxic antibodies in systemic lupus erythematosus patients and their relatives: reactivity with the HLA antigenic molecular complex. (1980) (36)
Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAFV600E melanoma (2015) (36)
HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition (2011) (36)
Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma. (2007) (36)
Modulation by adjuvants and carriers of the immunogenicity in xenogeneic hosts of mouse anti-idiotypic monoclonal antibody MK2-23, an internal image of human high molecular weight-melanoma associated antigen. (1993) (36)
Differential modulation by tumor necrosis factor and immune interferon of HLA class‐II antigens expressed by melanoma cells (1989) (36)
Iron and Ferritin Modulate MHC Class I Expression and NK Cell Recognition (2019) (36)
Differential regulatory role of monomorphic and polymorphic determinants of histocompatibility leukocyte antigen class I antigens in monoclonal antibody OKT3-induced T cell proliferation. (1987) (35)
Tumor microenvironment immune response in pancreatic ductal adenocarcinoma patients treated with neoadjuvant therapy. (2020) (35)
A radioimmunometric antibody-binding assay for evaluation of xenoantisera to melanoma-associated antigens. (1979) (35)
Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. (2013) (35)
Binding parameters and idiotypic profile of the whole immunoglobulin and Fab' fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight-melanoma associated antigen. (1992) (35)
HLA Class I Heavy Chain Epitope Mimicry by Monoclonal Antibody HC-10-Specific Peptide (2003) (35)
HL-A antigens in serum and urine: isolation, characterization, and immunogenic properties. (1976) (35)
Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma. (2011) (35)
The impact of monoclonal antibodies on the study of human malignant melanoma (1983) (35)
Modulation of tumor associated antigen expression and shedding by recombinant human leukocyte and fibroblast interferons. (1985) (34)
Expression and modulation by cytokines of the intercellular adhesion molecule‐1 (ICAM‐1) in human central nervous system tumor cell cultures (1990) (34)
Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature (2018) (34)
Fine Specificity of High Molecular Weight-Melanoma-Associated Antigen-Specific Cytotoxic T Lymphocytes Elicited by Anti-Idiotypic Monoclonal Antibodies in Patients with Melanoma (2004) (34)
Anti-HLA-B7,B27,Bw42,Bw54,Bw55,Bw56, Bw67,Bw73 monoclonal antibodies: specificity, idiotypes, and application for a double determinant immunoassay. (1988) (34)
Cytotoxic antibodies to cultured melanoma cells in the sera of melanoma patients. (1977) (34)
Syngeneic antiidiotypic antisera to murine antihuman high-molecular-weight melanoma-associated antigen monoclonal antibodies. (1987) (34)
Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer (2012) (34)
Changes in HL-A antigen profiles on SV40-transformed human fibroblasts. (1976) (34)
HLA and cancer: 12th International Histocompatibility Workshop study (1997) (34)
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma. (2016) (33)
Sustained high levels of circulating chaperoned interleukin-6 after active specific cancer immunotherapy. (1994) (33)
Human high-molecular-weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody TK7-371. (1991) (33)
Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (33)
Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight‐melanoma associated antigen (HMW‐MAA) specific monoclonal antibody (2005) (33)
Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells. (2007) (33)
Analysis of the Expression of I‐Ak‐like Antigens in Murine Fetal and Adult Tissues with the Monoclonal Antibody 10–2.16 (1981) (33)
Human High Molecular Weight–Melanoma-Associated Antigen: Utility for Detection of Metastatic Melanoma in Sentinel Lymph Nodes (2008) (33)
NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance. (2006) (33)
Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer (2015) (32)
β2-Microglobulin gene mutations in human melanoma cells: molecular characterization and implications for immune surveillance (1997) (32)
Peptide and Dendritic Cell Vaccines (2006) (32)
Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers. (2017) (32)
Effect of monoclonal antibodies (MoAb) to class I and class II HLA antigens on lectin- and MoAb OKT3-induced lymphocyte proliferation. (1985) (31)
INTERACTION OF HISTOCOMPATIBILITY (HL-A) ANTIBODIES AND COMPLEMENT WITH SYNCHRONIZED HUMAN LYMPHOID CELLS IN CONTINUOUS CULTURE (1973) (31)
Melanoma targeting with a cocktail of monoclonal antibodies to distinct determinants of the human HMW-MAA. (1989) (31)
Proteomic profile of melanoma cell‐derived small extracellular vesicles in patients’ plasma: a potential correlate of melanoma progression (2021) (31)
Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression (2003) (31)
212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. (2017) (31)
Missing HLA class I expression on Daudi cells unveils cytotoxic and proliferative responses of human γδ T lymphocytes (2002) (31)
Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus (2008) (31)
Immunotherapy of Malignant Diseases (2003) (31)
Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. (1995) (31)
Heterogeneity of HLA-A,B, Ia-like, and melanoma-associated antigen expression by human melanoma cell lines analyzed with monoclonal antibodies and flow cytometry. (1982) (31)
Differential modulation by recombinant immune interferon of the expression and shedding of HLA antigens and melanoma associated antigens by a melanoma cell line resistant to the antiproliferative activity of immune interferon. (1985) (31)
Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. (2005) (31)
The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses. (2020) (31)
Role of Apollon in Human Melanoma Resistance to Antitumor Agents That Activate the Intrinsic or the Extrinsic Apoptosis Pathways (2012) (31)
Differential clinical significance of αvB3 expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes (2000) (31)
A new B cell differentiation antigen (BDA) on normal and leukemic human B lymphocytes that is distinct from known DR (Ia-like) antigens. (1978) (30)
Differential expression of constitutive and inducible proteasome subunits in human monocyte‐derived DC differentiated in the presence of IFN‐α or IL‐4 (2009) (30)
Differential susceptibility of cultured human melanoma cell lines to enhancement by retinoic acid of intercellular adhesion molecule 1 expression. (1992) (30)
Human melanoma : from basic research to clinical application (1990) (30)
A double determinant immunoassay for HLA class I typing using serum as an antigen source. (1987) (30)
CSPG4 as a prognostic biomarker in chordoma. (2016) (30)
Specific Immunotherapy of Cancer With Vaccines (1993) (30)
Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibodies MK2-23. Experimental studies and clinical trials in patients with malignant melanoma. (1993) (29)
Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. (2004) (29)
HLA class I downregulation is associated with enhanced NK‐cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors (2015) (29)
Differential Immunogenicity of Two Peptides Isolated by High Molecular Weight-Melanoma-Associated Antigen-Specific Monoclonal Antibodies with Different Affinities1 (2005) (29)
Selection and Utilization of Monoclonal Antibody Defined Melanoma Associated Antigens for Immunoscintigraphy in Patients with Melanoma (1988) (29)
Potential of palladium-109-labeled antimelanoma monoclonal antibody for tumor therapy. (1984) (29)
Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions: association with lack of spontaneous regression (2003) (29)
Soluble HL‐A antigens in serum. I. Isolation and Purification (1975) (29)
HLA antigen changes in malignant tumors of mammary epithelial origin: molecular mechanisms and clinical implications. (2004) (28)
MHC-like molecules in some nonmammalian vertebrates can be detected by some cross-reactive monoclonal antibodies. (1990) (28)
Serologic and immunochemical characterization of HLA-A9 xenoantisera. (1978) (28)
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. (2020) (28)
Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity. (2007) (27)
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death (2013) (27)
Sonographic criteria for differentiation of benign and malignant solid breast lesions: size is of value (2006) (27)
Increased level of serum HLA class I antigens in patients with systemic lupus erythematosus. Correlation with disease activity (1998) (27)
Immunogenicity of human B cell antigens solubilized from cultured human lymphoid cells. (1977) (27)
Fate of HL-A antigens in aging cultured human diploid cell strains. II. Quantitative absorption studies. (1973) (27)
Stimulation of lymphocyte transformation by streptococcal type M1 protein: relationship to HL-A antigens. (1972) (27)
Melanoma Antigens and Antibodies (1982) (27)
A rapid microtechnique for in vitro stimulation of human lymphocytes by phytohemagglutinin. (1973) (27)
Human T lymphocytes in aging and malignancy: abnormalities in PHA-induced Ia antigen expression and in functional activity in autologous and allogeneic MLR. (1983) (27)
αvβ3 expression on blood vessels and melanoma cells in primary lesions; differential association with tumor progression and clinical prognosis (2000) (27)
Comparison of histocompatibility antigens on cultured human tumor cells and fibroblasts by quantitative antibody absorption and sensitivity to cell-mediated cytotoxicity. (1976) (26)
Immunotherapy of melanoma: the good news, the bad ones and what to do next. (2003) (26)
212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models (2018) (26)
HLA Class II Antigens (1986) (26)
HLA-G 2012 conference: the 15-year milestone update. (2013) (26)
Immunohistochemical detection of antigen in human primary and metastatic melanomas by the monoclonal antibody 140.240 and its possible prognostic significance (1987) (26)
Cancer immunotherapy: Progress and challenges in the clinical setting (2011) (26)
Immunogenicity of HLA antigens purified from serum. (1977) (25)
In vitro elimination of epidermal growth factor receptor‐overexpressing cancer cells by CD32A‐chimeric receptor T cells in combination with cetuximab or panitumumab (2019) (25)
Antigenic profile of human melanoma cells. Analysis with monoclonal antibodies to histocompatibility antigens and to melanoma‐associated antigens (1983) (25)
EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3 (2014) (25)
The HDAC Inhibitor Domatinostat Promotes Cell Cycle Arrest, Induces Apoptosis and Increases Immunogenicity of Merkel Cell Carcinoma Cells. (2020) (24)
Melanoma-associated hypopigmentation: where are the antibodies? (1996) (24)
Typing of serum-soluble HLA-B27 antigen by ELISA. (1993) (24)
Enhancing effect of anti-HLA class I monoclonal antibodies on T cell proliferation induced via CD2 molecule. (1988) (24)
Decreased expression of mitochondrial miR-5787 contributes to chemoresistance by reprogramming glucose metabolism and inhibiting MT-CO3 translation (2019) (24)
Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing. (1996) (24)
Antibody-coated protein A-bearing Staphylococcus aureus: a versatile and stable immune reagent. (1979) (24)
Imprinting of Lymphocytes with Melanoma Antigens Acquired by Trogocytosis Facilitates Identification of Tumor-Reactive T Cells (2013) (23)
Biosynthesis and intracellular processing of four human melanoma associated antigens. (1986) (23)
Interferon regulatory factor 8 mediates tumor-induced inhibition of antigen processing and presentation by dendritic cells (2009) (22)
Radioimmunodetection of Melanoma: Preliminary Results of a Prospective Study (1986) (22)
Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors (2016) (22)
Human Tumor‐Associated Antigen Mimicry by Anti‐idiotypic Antibodies Immunogenicity and Clinical Trials in Patients with Solid Tumors a (1993) (22)
HUMORAL SENSITIZATION IN PAROUS WOMEN: CYTOTOXIC ANTIBODIES TO NON HL‐A ANTIGENS (1976) (22)
Similar ectopic expression of ICAM-1 and HLA class II molecules in hypertrophic scars following thermal injury. (1994) (22)
Observations on certain enzyme activites of normal human red cells treated with sulfhydryl compounds. (1966) (22)
Immunochemical characterization of a human high molecular weight — melanoma associated antigen identified with monoclonal antibodies (2004) (22)
Tissue distribution of Ia-like antigens in different species: analysis with monoclonal antibodies. (1981) (22)
Circadian variations of autologous mixed lymphocyte reactions and endogenous cortisol. (1985) (22)
Suppression of human melanoma growth in nude mice injected with anti high-molecular-weight melanoma-associated antigen monoclonal antibody 225.28S conjugated to purothionin. (1985) (22)
Differential contribution of TAP and tapasin to HLA class I antigen expression (2008) (22)
Serological and immunochemical analysis of the specificity of xenoantiserum 8986 elicited with hybrids between human melanoma cells and murine fibroblasts. (1981) (22)
Association of HL‐A Antigens and β2‐Microglobulin: Concepts and Questions (1974) (21)
Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells (2021) (21)
Analysis of human tumor cells for Ia-like antigens with monoclonal antibodies. (1981) (21)
Early Hematopoietic Zinc Finger Protein Prevents Tumor Cell Recognition by Natural Killer Cells1 (2009) (21)
SEROLOGICAL CHARACTERIZATION OF NATURAL ANTIHUMAN LYMPHOCYTOTOXIC ANTIBODIES IN MAMMALIAN SERA (1973) (21)
Serologic cross-reactivity between H-2 and HL-A antigens. I. Specific reactivity of rabbit anti-HL-A sera against murine cells. (1972) (21)
Establishment of paired tumor cells and autologous virus‐transformed cell lines to define humoral immune responses in melanoma and sarcoma patients (1978) (21)
Specificity of lymphocytotoxic anti-human antibodies in normal rabbit sera. (2008) (21)
Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins. (2018) (21)
Modulation of the antigenic phenotype of human melanoma cells by differentiation-inducing and growth-suppressing agents. (2008) (21)
Antigen Presentation Machinery (APM) Modulation and Soluble HLA Molecules in the Tumor Microenvironment: Do They Provide Tumor Cells with Escape Mechanisms from Recognition by Cytotoxic T Lymphocytes? (2006) (21)
Idiotypes in medicine : autoimmunity, infection and cancer (1997) (21)
Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells. (2010) (21)
Tumor associated antigen (TAA) mimicry and immunotherapy of malignant diseases from anti-idiotypic antibodies to peptide mimics. (2001) (21)
Specificity and functional characteristics of anti-HLA-A mAbs LGIII-147.4.1 and LGIII-220.6.2. (2003) (21)
Current Trends in Histocompatibility (1981) (21)
Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor. (1999) (21)
IL-27 in Human Secondary Lymphoid Organs Attracts Myeloid Dendritic Cells and Impairs HLA Class I–Restricted Antigen Presentation (2014) (20)
FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011” (2012) (20)
Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2. (2005) (20)
EXPRESSION AND SUSCEPTIBILITY TO MODULATION BY INTERFERONS OF HLA CLASS I AND II ANTIGENS ON MELANOMA CELLS. IMMUNOHISTOCHEMICAL ANALYSIS AND CLINICAL RELEVANCE (1986) (20)
Expression and genetic analysis of transporter associated with antigen processing in cervical carcinoma. (2007) (20)
A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells (2008) (20)
Analysis of the NIH workshop monoclonal antibodies to human melanoma antigens. (1982) (20)
Bone marrow B-cell clonal expansion in type II mixed cryoglobulinaemia: association with nephritis. (2007) (20)
THE ROLE OF BETA‐2 MICROGLOBULIN IN TEMPERATURE‐SENSITIVE AND INTERFERON‐γ‐INDUCED EXOCYTOSIS OF HLA CLASS I MOLECULES (1992) (20)
Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients (2011) (19)
HLA-A,B antigens Ia-like antigens, and tumor-associated antigens on prostate carcinoma cell lines: serologic and immunochemical analysis with monoclonal antibodies. (1981) (19)
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”, Napoli, December 5th-8th 2013 (2014) (19)
Indirect rosette microassay to characterize human melanoma-associated antigens recognized by operationally specific xenoantisera. (1980) (19)
Chemical modulation of cell surfaces by sulfhydryl compounds: effect on C3b receptors. (1974) (19)
lncRNA CISAL Inhibits BRCA1 Transcription by Forming a Tertiary Structure at Its Promoter (2020) (19)
Effect of recombinant fibroblast interferon and recombinant immune interferon on growth and the antigenic phenotype of multidrug-resistant human glioblastoma multiforme cells. (1991) (19)
β2‐μ‐free HLA class I heavy chain levels in sera of healthy individuals. Lack of association with β2‐μ‐associated HLA class I heavy chain levels and HLA phenotype (1999) (19)
Intracellular antigens as targets for antibody based immunotherapy of malignant diseases (2015) (19)
Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma (2017) (19)
Current trends in tumor immunology (1979) (19)
HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease. (2020) (19)
Approaches for the isolation of biologically functional tumor-associated antigens. (1977) (19)
Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia (2021) (19)
Purification by ammonium sulfate precipitation of bacteriophage lambda gt11 DNA for restriction analysis of cloned cDNA inserts. (1988) (19)
Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours (2018) (19)
Anti-idiotypes and their application under autoimmune, neoplastic, and infectious conditions. (1994) (19)
Molecular heterogeneity and shedding of a high-molecular-mass melanoma-associated antigen identified with monoclonal antibodies. (1982) (19)
Differential clinical significance of alpha(v)Beta(3) expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes. (2000) (19)
A recombinant single‐chain human class II MHC molecule (HLA‐DR1) as a covalently linked heterotrimer of α chain, β chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens (1997) (18)
Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors (2015) (18)
Regression of human melanoma xenografts in nude mice injected with methotrexate linked to monoclonal antibody 225.28 to human high molecular weight-melanoma associated antigen (2005) (18)
BASIC SCIENCE REVIEW (2002) (18)
Antibodies as Carriers of Cancer Chemotherapeutic Agents a (1985) (18)
Distribution of a cross-species melanoma-associated antigen in normal and neoplastic human tissues. (1985) (18)
HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy. (2021) (18)
A sandwich assay to detect and characterize syngeneic anti-idiotypic antibodies to murine anti-HLA and tumor associated antigen monoclonal antibodies. (1986) (18)
ADCC of Cultured Human Melanoma Cells: Analysis with Monoclonal Antibodies to Human Melanoma‐associated Antigens (1981) (18)
Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells (2015) (18)
Effect of inhibitors of macromolecular synthesis on HL-A antibody mediated lysis of cultured lymphoblasts. (2008) (18)
CHAPTER 21 – SEROLOGIC DETECTION OF SOLUBLE HL-A ANTIGENS (1972) (18)
Murine antiidiotypic monoclonal antibodies that bear the internal image of HLA-DR allospecificities. (1989) (18)
Differential induction by immune interferon of the gene products of the HLA-D region on the melanoma cell line MeWo and its metastatic variant MeM 50-10. (1988) (18)
Cloning and in vitro expression of a melanoma-associated antigen immunogenic in patients with melanoma. (1991) (18)
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7 th2010" (2011) (18)
A primary amelanotic melanoma of the vagina diagnosed by immunocytochemistry (1989) (17)
Leukocyte antigen-antibody reaction and lysis of paroxysmal nocturnal hemoglobinuria erythrocytes. (1970) (17)
Antigenic profile of mucosal melanoma lesions (1994) (17)
Melanoma biology and progression. (2001) (17)
Structural Basis of Antigen Mimicry in a Clinically Relevant Melanoma Antigen System* (2005) (17)
Serological methods to detect anti-idiotypic antibodies. (1989) (17)
Idiotypic cascade in the human high molecular weight melanoma‐associated antigen system: Fine specificity and idiotypic profile of anti‐anti‐idiotypic monoclonal antibodies (1993) (17)
IRX-2, a Novel Immunotherapeutic, Enhances Functions of Human Dendritic Cells (2013) (17)
Differential effect of human and mouse beta 2-microglobulin on the induction and the antigenic profile of endogenous HLA-A and -B antigens synthesized by beta 2-microglobulin gene-null FO-1 melanoma cells. (1993) (17)
Modulation by MHC class I antigens of the biology of melanoma cells. Non-immunological mechanisms. (1993) (17)
Differential segregation patterns of human chromosomes in somatic cell hybrids constructed with human B-lymphocytes and human melanoma cells. (1982) (17)
Activation of human complement by human lymphoid cells sensitized with histocompatibility alloantisera. (1973) (17)
Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma (2019) (17)
Cross reaction of monoclonal antibodies to human MHC class I and class II products with bovine lymphocyte subpopulations. (1984) (17)
Response to: Circulating Tumor Cells and Detection of Melanoma-Associated Antigen HMW-MAA in the Serum of Melanoma Patients (2006) (17)
IRF-1 and p65 mediate upregulation of constitutive HLA-A antigen expression by hepatocellular carcinoma cells. (2009) (17)
Anti-idiotypic monoclonal antibodies reacting with idiotope on isolated-denatured chains of an anti-CD4 monoclonal antibody. (1991) (17)
Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016 (2017) (16)
Detection of H-2 antigens in serum. (1975) (16)
Inhibition by anti‐HLA class II monoclonal antibodies of monocyte‐dependent T cell proliferation induced by monoclonal antibody OKT3 (1987) (16)
Synergistic in vitro and in vivo anti-tumor effect of daunomycin-anti-96-kDa melanoma-associated antigen monoclonal antibody CL 207 conjugate and recombinant IFN-gamma. (1988) (16)
Expression of H-2 antigens during growth of cultured tumor cells. (1972) (16)
Autologous B lymphoblastoid cell lines and long-term cultured T cells as stimulators in the mixed lymphocyte reaction: analysis of the role of HLA class II antigens as stimulatory molecules. (1986) (16)
A third polypeptide associated with heavy and light chain subunits of class I HLA antigens in immune interferon‐treated human melanoma cells (1985) (16)
EGFR-mediated tumor immunoescape (2013) (16)
Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding β2-microglobulin genes (2009) (16)
Antigenic profile and functional characterization of human peritoneal macrophages. (1985) (16)
Wide tissue distribution of axolotl class II molecules occurs independently of thyroxin (1998) (16)
Immunodiagnostic and immunotherapeutic applications of anti human melanoma associated antigen monoclonal antibodies. (1989) (16)
Ontogeny of human Ia antigens. (1982) (16)
The laboratory substitutes of the red cell of paroxysmal nocturnal haemoglobinuria (PNH): PNH-like red cells. (1972) (16)
Dendritic cell maturation in HCV infection: altered regulation of MHC class I antigen processing-presenting machinery. (2014) (16)
Negative signaling by anti-HLA class I antibodies is dependent upon two triggering events. (1998) (15)
Serological, functional, and immunochemical characterization of a monoclonal antibody (MoAb Q2/70) to human Ia-like antigens. (1980) (15)
A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3–Specific CAR T Cells in Solid Tumors (2021) (15)
Ultrastructural alterations in human lymphoblastoid B cell lines treated with tunicamycin. (1981) (15)
Crystal structure of an anti-anti-idiotype shows it to be self-complementary. (1996) (15)
Natural cytotoxicity and antibody-dependent cellular cytotoxicity of human lymphocytes depleted of HLA-DR bearing cells with monoclonal HLA-DR antibodies. (1980) (15)
T cells from patients with chronic liver diseases: abnormalities in PHA-induced expression of HLA class II antigens and in autologous mixed-lymphocyte reactions. (1986) (15)
Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies (2009) (15)
Expression of HL-A antigens on the surface of cultured human lymphoid cells: effect of inhibitors of protein and nucleic acid synthesis. (2008) (15)
Sulfation and molecular weight of fibronectin shed by human melanoma cells. (1981) (15)
Syngeneic antiidiotypic monoclonal antibodies to the murine anti-HLA-DR,DP monoclonal antibody CR11-462. (1988) (15)
Human T cells in cord blood: abnormalities in IA antigens induction by phytohemagglutinin and in autologous mixed lymphocyte reactions. (1984) (15)
Overexpression of miR-489 enhances efficacy of 5-fluorouracil-based treatment in breast cancer stem cells by targeting XIAP (2017) (15)
Normal human lymphocytes treated in vitro with the sulfhydryl compound AET: relationship to the lymphocytes of paroxysmal nocturnal hemoglobinuria. (1971) (15)
Isolation of Ia-like antigen-bearing cells from human peripheral lymphocytes through the use of a monoclonal antibody to framework determinants of Ia-like antigens. (1980) (15)
CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes (2020) (15)
Human melanoma-associated antigens. (1989) (15)
Comparison of features of carcinogen-transformed human cells in vitro with sarcoma-derived cells. (1988) (15)
HLA class II antigens : a comprehensive review of structure and function (1986) (15)
Functional idiotopes: tumor antigen-directed expression of CD8+ T-cell epitopes nested in unique NH2-terminal VH sequence of antiidiotypic antibodies? (2005) (15)
Missing HLA class I expression on Daudi cells unveils cytotoxic and proliferative responses of human gammadelta T lymphocytes. (2002) (15)
Structural polymorphism of the β chain of human HLA-DR antigens (1980) (15)
Cross-reactivity of murine anti-human high molecular weight-melanoma associated antigen monoclonal antibodies with guinea pig melanoma cells. (1987) (14)
Cytoplasmic melanoma‐associated antigen (CYT‐MAA) serum level in patients with melanoma: A potential marker of response to immunotherapy? (2006) (14)
Detection of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma. (2014) (14)
Targeting CSPG4 for isolation of melanoma cell-derived exosomes from body fluids (2020) (14)
Partial amino acid sequence of HLA-A9 antigen purified with a specific xenoantiserum. (1978) (14)
Increased serum levels of β2m‐free HLA class I heavy chain in multiple myeloma (1999) (14)
Red Cell Acetylcholinesterase Activity in Autoimmune Haemolytic Anaemias (1970) (14)
Active specific immunotherapy with antiidiotypic antibodies in patients with solid tumors. (1989) (14)
Characterization of the specificity of DR monoclonal antibodies. (1979) (14)
European multicentre study on melanoma immunoscintigraphy by means of 99mTc-labelled monoclonal antibody fragments. The European Multicentre Study Group. (1990) (14)
Hidden Immunotherapy Targets Challenge Dogma (2011) (14)
Transfer and co-amplification of a gene encoding a 96-kDa immune IFN-inducible human melanoma-associated antigen. Preferential expression by mouse melanoma host cells. (1988) (14)
Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling (2021) (14)
Differential tissue distribution and ontogeny of DC-1 and HLA-DR antigens (2004) (14)
The free and the β2-microglobulin-associated heavy chains of HLA-A, B alloantigens share the antigenic determinant recognized by the monoclonal antibody Q1/28 (2004) (14)
CD16-158-Valine Chimeric Receptor T Cells Overcome the Resistance of KRAS-mutated Colorectal Carcinoma Cells to Cetuximab (2019) (14)
The immunologic and molecular profiles of HLA antigens isolated from urine. (1977) (13)
ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells (2017) (13)
Antibody-induced association between discrete regions of HLA class I and II antigens. (1987) (13)
Cell surface markers on epithelial-Burkitt hybrid cells superinfected with Epstein-Barr virus. (1977) (13)
Significance of the intraindividual variability of HLA IgG antibodies in renal disease patients observed with different beadsets monitored with two different secondary antibodies on a Luminex platform (2018) (13)
Serologically detectable human melanoma-associated antigens are not genetically linked to HLA-A and B antigens. (1979) (13)
Molecular characterization of the HLA-Cw*0409N allele. (2002) (13)
Effect of Tunicamycin on the Assembly and Antigenicity of HLA Antigens: Analysis with Monoclonal Antibodies (1981) (13)
Human High Molecular Weight‐melanoma Associated Antigen as a Target for Active Specific Immunotherapy (1988) (13)
Inhibitory effect of a low dose of prednisone on PHA-induced Ia antigen expression by human T cells and on proliferation of T cells stimulated with autologous PHA-T cells. (1983) (13)
New tridimensional approach to the evaluation of the spine through surface measurement: the BACES system. (2002) (13)
Distinct functional domains on the recombinant human immune interferon molecule. (1986) (13)
CD4-Dependent Potentiation of a High Molecular Weight-Melanoma-Associated Antigen-Specific CTL Response Elicited in HLA-A2/Kb Transgenic Mice1 (2006) (13)
Characterization of human afferent lymph dendritic cells from seroma fluids (2013) (13)
Induction and functional characterization of β 2‐microglobulin (β2‐μ)‐free HLA class I heavy chains expressed by β2‐μ‐deficient human FO‐1 melanoma cells (1998) (13)
Cancer Immunotherapy Principles and Practice (2018) (13)
A QUANTITATIVE STUDY OF CROSS REACTIVITY IN THE HL‐A SYSTEM WITH HUMAN CULTURED LYMPHOID CELLS AND SOLUBLE HL‐A ANTIGENS (1973) (13)
Anti-tyrosinase antibodies participate in the immune response to vaccination with anti-idiotypic antibodies mimicking the high-molecular-weight melanoma-associated antigen (1995) (13)
Utilization of cultured human lymphoid cells for detection of humoral sensitization in prospective recipients of kidney transplants. (1975) (13)
A Degenerate HLA-DR Epitope Pool of HER-2/neu Reveals a Novel In vivo Immunodominant Epitope, HER-2/neu88-102 (2010) (13)
Role of HLA class I and class II antigens in activation and differentiation of B cells. (1987) (13)
Development and characterization of mouse anti-human LMP2, LMP7, TAP1 and TAP2 monoclonal antibodies. (2008) (13)
Melanoma and immunotherapy bridge 2015 (2016) (13)
Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone (2017) (13)
Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts (2021) (13)
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy) (2019) (12)
The expression of HL-A antigens during the growth cycle of cultured human lymphoid cells. (1973) (12)
Serum HLA class I antigen levels in allogeneic bone marrow transplantation: a possible marker of acute GVHD. (1996) (12)
Alpha(v)beta3 expression on blood vessels and melanoma cells in primary lesions: differential association with tumor progression and clinical prognosis. (2000) (12)
Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review. (2021) (12)
Associated expression of HLA class I and class II antigens on melanoma cells in surgically removed metastases (1986) (12)
Evolution of studies of HLA class I antigen processing machinery (APM) components in malignant cells. (2013) (12)
HLA Typing: Methodology and Clinical Aspects (1982) (12)
Association of HL-A antigens andβ2-microglobulin at the cellular and molecular level (1975) (12)
Human melanoma-associated antigens identified with monoclonal antibodies (1982) (12)
In vitro differentiation and antigenic changes in human melanoma cell lines (2005) (12)
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage (2015) (12)
A transcriptional inhibitor induced in human melanoma cells upon ultraviolet irradiation. (1993) (12)
Molecular profiles of human melanoma-associated antigens. (1981) (12)
HLA class II molecules on monocytes regulate T cell proliferation through physical interaction in the CD3 activation pathway (1991) (12)
Immunotherapy dispenses with tumor antigens (2004) (12)
HL-A antigens, antibody, and complement in the lymphocytotoxic reaction. (1973) (12)
Functional and immunological characterization of the stimulation of human lymphocytes with a mitogen from group A streptococci (SM). (1982) (12)
High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy (2019) (12)
Major Histocompatibility Complex Class I-related Chain A and UL 16-Binding Protein Expression on Tumor Cell Lines of Different Histotypes : Analysis of Tumor Susceptibility to NKG 2 D-dependent Natural Killer Cell Cytotoxicity 1 (2002) (12)
Immunogenicity of soluble HL-A alloantigens. (1972) (11)
HLA class II molecules transduce accessory signals affecting the CD3 but not the interleukin-2 activation pathway in T blasts. (1993) (11)
Modulation by antiidiotypic monoclonal antibodies of immune lysis mediated by anti-HLA monoclonal antibodies. (1989) (11)
Induction of nuclear factor kappa B/Rel nuclear activity in human peripheral blood T lymphocytes by anti-HLA class I monoclonal antibodies. (1997) (11)
Increased level of serum HLA class I antigens in patients with systemic lupus in patients with systemic lupus erythematosus. Correlation with disease activity. (1998) (11)
Changes in Ia-like antigen expression on malignant human cells (2005) (11)
Methods for improving the immunogenicity and efficacy of cancer vaccines (2018) (11)
Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP‐1 inhibitor in combination with topoisomerase i inhibitor or radiation (2014) (11)
Murjne Anti-Idiotypic Monoclonal Antibodies to Syngeneic Antihuman High Molecular Weight-Melanoma Associated Antigen Monoclonal Antibodies: Development, Characterization, and Clinical Applications (1988) (11)
Monoclonal antibodies and tumor vaccines. (1990) (11)
The role of complement in the HL-A antibody-mediated lysis of lymphocytes. (1974) (11)
Levels of antigen processing machinery components in dendritic cells generated for vaccination of HIV-1+ subjects (2007) (11)
Expression of Ia-like antigens in human erythroid progenitor cells as determined by monoclonal antibodies and heteroantiserum to Ia-like antigens. (1981) (11)
Characterization of DR antigens on cultured melanoma cells by using monoclonal antibodies. (1980) (11)
Inhibition by anti-HLA class II monoclonal antibodies of monoclonal antibody OKT3-induced T cell proliferation. Studies at the mRNA level. (1990) (11)
The monoclonal xenoantibody Q6/64 recognizes a determinant expressed by certain gene products of the A and B loci of the HLA region (2004) (11)
Xenoantisera to allotypic specificities of HLA-A and B antigens. Serological characterization. (1979) (11)
Computationally Guided Design of Single-Chain Variable Fragment Improves Specificity of Chimeric Antigen Receptors (2019) (11)
An antiglobulin microcytotoxicity assay to analyze non-complement fixing monoclonal antibodies to human histocompatibility antigens. (1982) (11)
Ganglioside, adhesion molecule, and HLA antigen expression in basal cell carcinoma lesions. (1992) (11)
A rapid micromethod for direct H-2 typing of mouse cultured lymphoid cells. (1972) (11)
Immunochemical Analysis of the Antigenic Profile of Human Melanoma Cells with Monoclonal Antibodies (1982) (10)
Characterization of Human Afferent Lymph Dendritic Cells from Seroma Fluids (2013) (10)
Differential susceptibility to modulation by recombinant immune interferon of HLA-DR and -DQ antigens synthesized by melanoma COLO 38 cells. (1986) (10)
Extraction and purification of soluble HL-A antigens from exhausted media of human lymphoid cell lines. (1973) (10)
Structural profile of idiotype, anti‐idiotype and anti‐anti‐idiotype monoclonal antibodies in the HLA‐DQ3 antigenic system (1994) (10)
HLA (A*0201) mimicry by anti-idiotypic monoclonal antibodies. (1998) (10)
Expression of the H‐2 Antigenic Complex on Murine Haematopoietic Stem Cells (1982) (10)
A Biologic and Chemical Profile of Histocompatibility Antigens (1975) (10)
Specificity of Mimotope-Induced Anti-High Molecular Weight-Melanoma Associated Antigen (HMW-MAA) Antibodies Does Not Ensure Biological Activity (2011) (10)
The HLA System in Clinical Transplantation (1993) (10)
Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review. (2021) (10)
Cutaneous Melanoma and Precursor Lesions (1984) (10)
Syngeneic anti-idiotypic antisera to murine anti-HLA class II monoclonal antibodies. (1987) (10)
Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons (2005) (10)
Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives. (2017) (10)
Survival of the fittest or best adapted: HLA-dependent tumor development (2010) (10)
Immunogenicity of DR antigens isolated from body fluids. (1980) (10)
Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model (2007) (10)
Role of antigen density in immune lysis of interferon-treated human lymphoid cells: analysis with monoclonal antibodies to the HLA-A,B antigenic molecular complex and to Ia-like antigens. (1981) (10)
Immunochemical and functional analysis of Ia-like antigens on human monocyte-macrophages with monoclonal antibodies. (1982) (10)
The monoclonal antibody AC1.59 defines a new polymorphic determinant on HLA-DR molecules. (2008) (10)
T-cell-based immunotherapy of melanoma: what have we learned and how can we improve? (2004) (10)
THE EARLY POSTTRANSPLANT PROGNOSIS OF ACUTE RENAL ALLOGRAFT REJECTION AS DETERMINED BY DETECTION OF CYTOTOXIC ANTIBODIES TO LYMPHOID B CELL LINES (1984) (10)
Distribution of antigenic determinants recognized by three monoclonal antibodies (Q2/70, Q5/6 and Q5/13) on human Ia-like alloantigens and on their subunits (2005) (10)
Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases. (2005) (9)
Have tumor cells learnt from microorganisms how to fool the immune system? Escape from immune surveillance of tumors and microorganisms: emerging mechanisms and shared strategies. (2000) (9)
Beta2-micro-free HLA class I heavy chain levels in sera of healthy individuals. Lack of association with beta2-micro-associated HLA class I heavy chain levels and HLA phenotype. (1999) (9)
Rewarding patient-directed research: Excellence in Translational Medicine Award (2006) (9)
Rabbit complement in the lymphocytotoxicity test. (2008) (9)
Radioimmunodetection of Malignant Melanoma with Radiolabelled (131I, 123I, 111In, 99mTc) Monoclonal Antibodies and F(ab′)2 Fragments (1986) (9)
A fresh look at an old story: revisiting HLA class II antigen expression by melanoma cells (2006) (9)
Lack of a role of monocytes in the inhibition by monoclonal antibodies to monomorphic and polymorphic determinants of HLA class I antigens of PHA-P-induced peripheral blood mononuclear cell proliferation. (1989) (9)
Inhibition by anti-HLA class I mAb of IL-2 and IL-2 receptor synthesis in lymphocytes stimulated with PHA-P. (1990) (9)
Histiocytosis X arising in Hodgkin's disease: immunophenotypic characterization with a panel of monoclonal antibodies (2005) (9)
Expression of histocompatibility antigens during the growth cycle of cultured lymphoid cells. (1974) (9)
Selective in vitro toxicity of purothionin conjugated to the monoclonal antibody 225.28S to a human high-molecular-weight melanoma-associated antigen (2004) (9)
Rosetting of human T lymphocytes with goat red blood cells: effect of treatment with 2-aminoethylisothiouronium bromide (AET) and comparison with AET treated sheep red blood cells. (1979) (9)
Major histocompatibility antigen expression in the liver in acquired immunodeficiency syndrome. (1987) (9)
Stimulation of human T lymphocytes by PHA-activated autologous T lymphocytes: Analysis of the role of Ia-like antigens with monoclonal antibodies (2005) (9)
Serum levels of beta-2-microglobulin-free heavy chain of HLA class I antigen in healthy individuals: relationship to their class I allotype. (1999) (9)
Molecular Heterogeneity of a High Molecular Weight Human Melanoma Associated Antigen Detected by Monoclonal Antibodies (1982) (9)
B7-H3 targeted antibody-based immunotherapy of malignant diseases (2020) (9)
Role of the anatomic site in the association of HLA class I antigen expression level in metastases with clinical response to ipilimumab therapy in patients with melanoma (2020) (9)
Organ-specific metastases in melanoma: experimental animal models. (1993) (9)
Syngeneic anti-idiotypic antisera to murine monoclonal antibodies to monomorphic and polymorphic determinants of HLA class I antigens. (1987) (8)
Human Hepatitis B Virus Negatively Impacts the Protective Immune Crosstalk Between Natural Killer and Dendritic Cells (2021) (8)
Serological and molecular characterization of mouse anti-idiotypic monoclonal antibodies elicited with the syngeneic anti-HLA-A2,28 monoclonal antibody CR11-351. (1993) (8)
Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma (2020) (8)
Improvement by affinity chromatography on antiidiotypic monoclonal antibodies (MAbs) of immunoreactivity and in vivo targeting of radiolabelled anti‐HMW‐MAA MAb TP61.5 in nude mice bearing human melanoma lesions (1991) (8)
Novel tumor antigen-specific monoclonal antibody-based immunotherapy to eradicate both differentiated cancer cells and cancer-initiating cells in solid tumors. (2014) (8)
Improving the Clinical Significance of Preclinical Immunotherapy Studies through Incorporating Tumor Microenvironment–like Conditions (2020) (8)
Effect of tumor size on the enhancement by gamma interferon of the localization of radiolabeled F(ab')2 fragments of anti-intercellular adhesion molecule-1 monoclonal antibodies in human colon carcinoma cells grafted in nude mice. (1992) (8)
Tissue distribution and molecular profile of a differentiation antigen detected by a monoclonal antibody (345.134S) produced against human melanoma cells (1982) (8)
Modulation of adhesion molecule CD54 expression on CD34+ hematopoietic progenitors. (1995) (8)
Purification of immunoreactive radiolabeled monoclonal antibodies with anti-idiotypic monoclonal antibodies. (1990) (8)
Humoral immunity in renal transplantation Detection of cytotoxic antibodies to lymphocyte antigens other than HLA-A,B,C and Ia-like antigens in patients with vascular graft rejection. (1981) (8)
Lysis of cultured human melanoma M10 cells by polyclonal xenoantibodies to melanoma-associated antigens. (1981) (8)
Human Melanoma Associated Antigens Identified with Monoclonal Antibodies: Characterization and Potential Clinical Application (1984) (8)
Cross-reactivity between HL-A and H-2 antigens. II. Allogeneic sensitization by xenogeneic soluble lymphocyte antigens (HL-A). (1973) (8)
Absence of DR antigens on human T lymphoid cells: serologic and immunochemical studies with xenoantisera. (1979) (8)
Analysis of the repertoire of anti-HLA antibodies with anti-idiotypes to a murine anti-HLA-A2,A28 monoclonal antibody. (1984) (8)
Contribution of dendritic cells FcγRI and FcγRIII to cross-presentation of tumor cells opsonized with the anti-MHC class I monoclonal antibodies (2007) (7)
Immune Escape: Tumor induced immune suppression and immune escape: Mechanisms and Possible Solutions (2005) (7)
Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting (2009) (7)
AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma (2016) (7)
Molecular abnormalities in the expression of HLA class‐I antigens by melanoma cells (1991) (7)
Discordant expression of 2 Epstein-Barr virus-associated antigens, EBNA and RANA, in man-rodent somatic cell hybrids. (1981) (7)
IGKC and Prognosis in Breast Cancer–Response (2012) (7)
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy) (2018) (7)
Chemical and molecular nature of HL-A antigens. (1973) (7)
Soluble HLA Class I antigens in sera of patients with chronic hepatitis (1992) (7)
The Hla System in Clinical Transplantation: Basic Concepts and Importance (1992) (7)
Immunosuppressive activity of T cell clones generated from human T cells stimulated with autologous TPHA cells. (1987) (7)
Typing of cultured human lymphoid cells. (1972) (7)
Monoclonal antibody OKT3-induced T cell proliferation: differential role of HLA class II determinants expressed by T cells and monocytes. (1990) (7)
Serologic specificity and crossreactivity of soluble HL-A alloantigens. (1972) (7)
Lack of DR antigens on human B-lymphocyte-mouse fibroblast hybrids that express HLA-A,B antigens. (1979) (7)
An enzyme-linked double antibody immunoassay to measure murine immunoglobulins--its application to determine the specific activity of radiolabeled monoclonal antibodies. (1985) (7)
HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. (2018) (7)
Characterization and Isolation of HL-A Antigens from Continuous Cultured Human Lymphocyte Cell Lines: A Report of Current Progress (1972) (7)
Immune checkpoint inhibitors for the treatment of melanoma (2022) (7)
Some enzymatic and metabolic activities of normal human erythrocytes treated in vitro with cephalothin. (1968) (7)
Pre-Clinical Evaluation of B7-H3-Specific Chimeric Antigen Receptor T-Cells for the Treatment of Acute Myeloid Leukemia (2018) (7)
HUMAN AND MURINE TUMOURS: CHANGES IN CELL SURFACE STRUCTURES CODED BY THE MAJOR HISTOCOMPATIBILITY COMPLEX REGION (1980) (7)
Receptors for sheep red blood cells on human B lymphoid WI-L2 cells. (1978) (7)
Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non–Small Cell Lung Cancer (2021) (7)
Novel ANO5 mutation c.1067G>T (p.C356F) identified by whole genome sequencing in a big family with atypical gnathodiaphyseal dysplasia (2018) (7)
Melanoma, immune surveillance, and immunotherapy. (1994) (7)
Emerging BRAF inhibitors for melanoma (2013) (7)
Characterization of rabbit antisera elicited with human LMP2- and LMP7-specific peptides and recombinant proteins. (1997) (6)
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy (2018) (6)
Inhibitory effect of normal mammalian sera on the rosette formation of human lymphocytes with sheep red blood cells. (1975) (6)
Use of monoclonal antibodies to investigate immunologic cross-reactivity of histocompatibility antigens from various animal species. (1980) (6)
Role of distinct domains of Ia antigens in autologous and allogeneic mixed lymphocyte reactions. (1983) (6)
Electron microscope study of PNH red cells and AET-treated normal red cells (PNH-like cells) (1971) (6)
Circulating tumor cells and detection of the melanoma-associated antigen HMW-MAA in the serum of melanoma patients. Authors' reply (2006) (6)
In Vivo Effect of the Conjugate of Monoclonal Antibody with Cytotoxic Agent on the Tumor Growth of Human Melanoma (1983) (6)
Expression of HL-A antigens on cultured human fibroblasts infected with mycoplasmas. (1973) (6)
Comparison of the Binding Parameters to Melanoma Cells of Antihuman High Molecular Weight‐Melanoma Associated Antigen (HMW‐MAA) Monoclonal Antibodies (mAb) and Syngeneic Anti‐Anti‐idiotypic (Anti‐Anti‐id) mAb a (1993) (6)
The Anti-Idiotypic Approach to Active Specific Immunotherapy of Malignant Melanoma (1997) (6)
Active Specific Immunotherapy of Malignant Melanoma with Anti‐idiotypic Monoclonal Antibodies (1993) (6)
Complement-dependent killing of human hematopoietic progenitor cells with noncomplement-fixing monoclonal antibodies in an antiglobulin assay. (1984) (6)
Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells (2019) (6)
Cross-reactivity between human and murine lymphocyte antigens: III. Reactivity of H-2 allo- and xenoantisera with human lymphoid cells (1974) (6)
Interferon-γ secretion by t(9;22) acute lymphoblastic leukemia-derived dendritic cells. (2011) (6)
HLA antigen expression in melanocytic lesions: is acquisition of HLA antigen expression a biomarker of atypical (dysplastic) melanocytes? (2012) (6)
Natural antibodies to human lymphocytes in murine strains. (1976) (6)
MHC class I-related antigen-processing machinery component defects in feline mammary carcinoma. (2012) (6)
A simple method for production of specific xenoantisera to human histocompatibility (HLA-A,-B,-C) antigens. (1978) (6)
Role of class II histocompatibility antigens in Staphylococcus aureus protein A-induced activation of human T lymphocytes. (1985) (6)
Distinction between malignant L cells and normal mouse fibroblasts by rosette formation with sheep red blood cells. (1975) (6)
Production and characterization of monoclonal antibodies against major histocompatibility complex class I chain-related gene A. (2008) (6)
Innovative Therapy, Monoclonal Antibodies and Beyond. (2017) (6)
Induction and functional characterization of beta2-microglobulin (beta2-mu)-free HLA class I heavy chains expressed by beta2-mu-deficient human FO-1 melanoma cells. (1998) (6)
Immunoreactivity and affinity of murine IgG monoclonal antibodies purified by caprylic acid precipitation. (1988) (6)
Preparation, Characterization, and Utilization of Monoclonal Antibodies to the Gene Products of the HLA-D Region, with Special Emphasis on Those to Polymorphic Determinants (1986) (6)
Cancer Stem Cell Resistance to Targeted Therapy (2019) (5)
A cytoplasmic human melanoma associated antigen as a marker of activation in lymphoid cells. (1987) (5)
Diversity in the fine specificity and idiotypic profile of mouse anti-HLA-DR monoclonal antibody elicited with the syngeneic anti-idiotypic monoclonal antibody F5-830. (1991) (5)
Association between induction of anti high molecular weight-melanoma associated antigen (HMW-MAA) immunity with mouse antiidiotypic monoclonal antibody (MoAb) MK2-23 and prolongation of survival in patients with melanoma. (2008) (5)
Melanoma initiating cells: where do we stand? (2015) (5)
The SPPL3-defined glycosphingolipid repertoire orchestrates HLA class I-mediated immune responses. (2021) (5)
Level of Ia-like antigens on human B and T lymphocytes. (1981) (5)
Evaluation of biotinylated cells as a source of antigens for characterization of their molecular profile (1998) (5)
High Antigen Processing Machinery component expression in Langerhans cells from melanoma patients' sentinel lymph nodes. (2017) (5)
Functional properties of anti-B-cell antigen alloantisera. (1977) (5)
Targeted radioimmunotherapy of triple negative breast cancer with CSPG4-specific 212Pb-labeled monoclonal antibody. (2016) (5)
Human high molecular weight‐melanoma associated antigen mimicry by mouse anti‐idiotypic MAb MK2‐23. Immunohistochemical analysis of the reactivity of anti‐anti‐idiotypic MAb with surgically removed melanoma lesions (2006) (5)
Expression of high molecular weight-melanoma associated antigen (HMW-MAA) in primary ALM lesions is associated with a poor prognosis. (2008) (5)
Lack of association of serologically detectable human melanoma-associated antigens with beta 2 microglobulin: serologic and immunochemical evidence. (1980) (5)
A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma (2020) (5)
Survival of cephalothin-treated erythrocytes. (1968) (5)
Histocompatibility Antigens, Tumor Microenvironment and Escape Mechanisms Utilized by Tumor Cells (2008) (5)
Isolation of viable melanoma cells from surgically removed lesions using dishes coated with monoclonal antibody to a high molecular weight melanoma associated antigen. (1983) (5)
IMMUNOREGULATORY PROPERTIES OF CD 44 + CANCER STEM-LIKE CELLS IN SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (2013) (5)
sHLA-STATTM class I, an ELISA for quantification of HLA antigens in serum (1991) (5)
A Comparison of the Cyclic Anhydride and Mixed Anhydride Methods for 111In-DTPA Chelation to Monoclonal Antibodies (1984) (5)
Surface ultramicroscopy of paroxysmal nocturnal haemoglobinuria erythrocytes. (1970) (5)
Immunotherapeutic approach to rheumatoid arthritis with anti-idiotypic antibodies to HLA-DR4. (1993) (5)
Immunochemical analysis of anti-HLA-A2, HLA-A3, and HLA-B27 xenoantisera elicited with hybrids between human and murine cells (2004) (5)
Isolation and Serological Evaluation of HL-A Antigens Solubilized from Cultured Human Lymphoid Cells (1974) (5)
Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells (2020) (5)
Purification by affinity chromatography with anti-idiotypic monoclonal antibodies of immunoreactive monoclonal antibodies following labeling with 188Re. (1997) (5)
Immune lysis of normal and AET-treated lymphocytes: a study of transmission and scanning electron microscopy. (1971) (5)
Mitogenic activity of anti-CD28 MoAb CLB-CD28/1 on peripheral blood mononuclear cells and its cooperation with other anti-T cells MoAb in the activation of purified T lymphocytes. (1990) (5)
Chondroitin Sulfate Proteoglycan-4 (CSPG4)-Specific Monoclonal Antibody 225.28 in Detection of Acute Myeloid Leukemia Blasts (2015) (5)
Fine specificity and idiotype diversity of a murine anti-HLA-DQw3 monoclonal antibody elicited with a syngeneic antiidiotypic monoclonal antibody. (1990) (5)
PERSISTENCE OF CYTOTOXIC ANTIBODIES TO HLA‐A,B,C ANTIGENS AND TO Ia‐LIKE ANTIGENS IN PAROUS WOMEN (1981) (5)
Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence (2013) (5)
Defective HLA Class I Expression and Patterns of Lymphocyte Infiltration in Chordoma Tumors. (2020) (5)
Harnessing host innate immunity may combat acquired resistance to BRAFi (2014) (5)
B7-H3-targeted radioimmunotherapy of human cancer. (2020) (5)
T‐cell receptors and IC AM‐1 expression in renal allografts during rejection (1991) (5)
Characterization of antigens on human lymphocytes coded by messenger RNA translated in vitro. (1982) (4)
Immunotherapeutics for head and neck squamous cell carcinoma stem cells (2020) (4)
CELLULAR AND MOLECULAR HETEROGENEITY OF H‐2Kk ANTIGENS (1981) (4)
IL-15/B7-H3 TriKEs-Based Immunotherapy for Pancreatic Ductal Adenocarcinoma (2019) (4)
DETECTION OF B CELL ANTIBODIES IN RENAL TRANSPLANT RECIPIENTS (1978) (4)
Active specific immunotherapy of malignant melanoma and peptide mimics of the human high-molecular-weight melanoma-associated antigen. (2001) (4)
Study of in Vitro Lysis of Paroxysmal Nocturnal Haemoglobinuria (PNH) and PNH‐like Red Cells (1972) (4)
Regulatory role of monomorphic and polymorphic determinants of HLA class I antigens in the proliferation of T cells stimulated by autologous and allogeneic B and T lymphoid cells. (1988) (4)
Induction of Differentiation in Human Melanoma Cells by the Combination of Different Classes of Interferons or Interferon Plus Mezerein a (1989) (4)
A monoclonal antibody to an allotypic determinant expressed by HLA-A2 and A28 alloantigens (1982) (4)
Accessory cell function of human melanoma cells in mitogen-induced T cell proliferation. (1988) (4)
Syngeneic Polyclonal and Monoclonal Antiidiotypic Antibodies to Murine Anti-Human High Molecular Weight-Melanoma Associated Antigen and Anti-HLA Monoclonal Antibodies (1987) (4)
PHA-T cells in systemic lupus erythematosus and in rheumatoid arthritis: abnormalities in HLA class II antigen induction and in autologous mixed lymphocyte reactions. (1986) (4)
Development of neoplastic phenotype following transfection of HNF cells with sarcoma DNA. (1989) (4)
Immunochemical and functional characterization of anti-idiotypic antibodies to a mouse anti-CD4 monoclonal antibody (1992) (4)
Interspecific DNA-mediated transfer and amplification of a gene specifying a Mr 100,000 human melanoma-associated cell surface glycoprotein. (1990) (4)
Isolation of human tumor-associated cell surface antigen-binding scFvs. (2002) (4)
Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation. (2014) (4)
Cancer immunotherapy targeting the HMW-MAA protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature (2010) (4)
Corrigendum to '212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models' [Nucl Med Biol 58 (2018) 67-73]. (2018) (4)
Class II HLA Antigens in Benign and Malignant Lesions of Melanocytic Origin (1986) (4)
Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression (2022) (4)
Reactivity patterns with HLA-A2 variants indicate lack of identity between determinants defined by monoclonal antibodies and cytotoxic-T-cell clones. (1984) (4)
Study of Two in Vitro Diagnostic Tests for Paroxysmal Nocturnal Haemoglobinuria (1973) (4)
Differential expression of HLA-DR allospecificities on antigen specific T cell clones. (2008) (4)
Analysis of the role of xenogeneic antigens in the proliferation of human T cells stimulated with autologous non-T cells and phytohemagglutinin-activated T cells. (1985) (4)
HUMORAL IMMUNITY IN KIDNEY TRANSPLANT RECIPIENT,S1 (1977) (4)
Improved tumor targeting of rhenium‐186‐labeled anti‐human high‐m.w. melanoma‐associated antigen monoclonal antibody 763.74 following purification with anti‐idiotypic monoclonal antibody MK2–23 (1998) (4)
Multidisciplinary approach to patient with malignant melanoma. (2013) (4)
Monoclonal Antibodies Recognizing Melanoma-Associated Antigens. (1987) (4)
The in Vitro Lysis of the Red Cells of Paroxysmal Nocturnal Haemoglobinuria by the Serum of Patients with Cirrhosis of the Liver (1969) (4)
Characterization of Human Null Cells Isolated from Peripheral Lymphocytes by a Simultaneous Double‐Rosetting Procedure (1981) (4)
sHLA-STATTMB27, an ELISA for HLA typing using serum (1991) (4)
Structural relationship between W4/W6 antigens and other surface markers on cultured human lymphoid cells as determined by the ‘lysostrip’ method (1978) (4)
Effects of inhibitors of macromolecular synthesis on cell surface expression of HL-A antigens. (1973) (4)
ANTIBODY‐DEPENDENT CELL‐MEDIATED CYTOTOXICITY USING MONOCLONAL ANTIBODIES REACTING WITH CEA a (1983) (4)
The major histocompatibility complex in man: biological and molecular approaches. (1976) (4)
Modulation of SignalTransducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFN A 2 b (2007) (4)
Ia-like and HLA-A,B antigens on tumor cells in long-term culture. (1981) (4)
Immunopathology of Melanoma with Monoclonal Antibodies (1990) (4)
Monoclonal Antibodies Directed Against Human la Antigens Detect an Evolutionary Conserved Epitope on Guinea Pig la Antigens With Unique Functional Properties (1984) (4)
A new approach to bifunctional chelate attachment to antibodies (1984) (3)
Molecular polymorphism of HLA-DR antigens isolated from Raji and Daudi lymphoblastoid cell lines (1980) (3)
Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy (2012) (3)
Correction to: Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram (2020) (3)
HETEROGENEITY IN THE ANTI‐HLA-DR IMMUNE RESPONSE ELICITED BY THE ANTIIDIOTYPIC MONOCLONAL ANTIBODY F5–444: ANALYSIS AT THE CLONAL LEVEL (1992) (3)
Allorecognition of an HLA-A*01 Aberrant Allele by an HLA Identical Family Member Carrying the HLA-A*0101 Allele1 (2006) (3)
Cancer Stem Cells: The Players of Immune Evasion from Immunotherapy (2019) (3)
Proliferative pathways in CD1- CD3+ CD4+ CD8+ T-prolymphocytic leukemic cells: analysis with monoclonal antibodies and cytokines. (1989) (3)
Appearance of receptors for Macaca speciosa red blood cells on human fibroblasts transformed by simian virus 40. (1980) (3)
Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy. (2022) (3)
Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAs (2021) (3)
Detection of HLA (Ia) and non-HLA specificities by "B-cell" antisera. (1977) (3)
HLA-D antigen disparity and HLA-DRw antibodies in intrafamilial renal allograft survival. (1979) (3)
HLA class I antigen downregulation in brain tumours (2001) (3)
Specific killing of human melanoma cells with an efficient 10B-compound on monoclonal antibodies. (1989) (3)
A Double Determinant Immunoassay (DDIA) with Monoclonal Antibodies to a Human High Molecular Weight Melanoma Associated Antigen (HMW-MAA) (1983) (3)
Identification with the monoclonal antibody 26.163 of a determinant shared by the beta chains of the gene products of the HLA-DR, DQ, and DP loci. (1986) (3)
The First International Conference on the Uses of Phenytoin in Dermatology December 12, 15, 1987 (1988) (3)
XENOANTISERA TO DRw ALLOSPECIFICITIES (1980) (3)
Handbook of monoclonal antibodies : applications in biology and medicine (1985) (3)
Can the "right" EGFR-specific mAb dramatically improve EGFR-targeted therapy? (2013) (3)
HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab (2022) (3)
Analysis by NMR Spectroscopy of the Structural Homology between the Linear and the Cyclic Peptide Recognized by Anti-human Leukocyte Antigen Class I Monoclonal Antibody TP25.99*210 (2000) (3)
Indirect rosette microassay: comparison of protein a with purified anti-Ig antibody (1980) (3)
Cells Activates Senescence and Increases Susceptibility to Cell-Mediated Cytotoxicity (2006) (3)
Increased beta2-microglobulin-free HLA class I heavy chain serum levels in the course of immune responses to viral antigens and to mismatched HLA antigens. (2000) (3)
HLA-DR antigens and mitogenic factors released by PWM-stimulated T lymphocytes share the framework determinant recognized by the monoclonal antibody Q5/13. (1981) (3)
Cancer Therapy : Preclinical CSPG 4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma (2012) (3)
Cross-reacting xenoantibodies to human and murine beta 2-microglobulin. (1979) (3)
Structural organization of human DR antigens and their murine analog, I-E antigens: serologic, genetic, and functional implications. (1979) (3)
Cytotoxicity of anti-beta 2-microglobulin xenoantisera to human and murine myeloid progenitor cells and lack of cross-reactivity with colony-stimulating activity. (1980) (3)
Immunochemical Characterization of a Human B Lymphocyte Differentiation Antigen (p65) (1980) (3)
Isolation and expansion of circulating tumor cells (CTC) from melanoma patients using a novel cell culture technique. (2012) (3)
Phase I trial of the anti-idiotypic monoclonal antibody (mAb) ACA-125 in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer. (2004) (3)
In‐Vitro Lysis of AET‐Treated Normal Red Cells (PNH‐like Cells) by Normal and Cirrhotic Sera (1969) (3)
Immunological and structural profile of a 96 kD human melanoma associated antigen with preferential distribution in metastases. (1988) (3)
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (3)
Expression of a sheep red blood cell receptor by a murine lymphoma. (1979) (3)
Active Specific Immunotherapy of Malignant Diseases—Breaking Tolerance to Self-Antigens with Tumor Associated Antigen Mimics (2000) (3)
Sera from volunteers immunized by planned blood transfusions as source of DR cytotoxic typing reagents. (1979) (3)
Erythrocyte glutathione reductase activity in chronic renal disease. (2009) (3)
Abstract 1676: Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. (2013) (3)
T-cell malignancies with mature phenotypes: altered cell cycle regulation by HLA class I molecules. (1991) (3)
Possible Involvement of C4 in the Mixed Lymphocyte Reaction (1976) (2)
Cancer Therapy : Clinical Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen – Speci fi c T-cell Immunity in Head and Neck Cancer Patients (2013) (2)
Determination of red cell acetylcholinesterase activity by diagnostic kit; modification of the method. (1970) (2)
Monoclonal antibodies and immunologic approaches to malignant tumors. (1983) (2)
Modulation of immune lysis of tumor cells by interferon. (1983) (2)
In vitro enhancement of the proliferative response of human T cells to autologous non-T cells by hydralazine. (1986) (2)
Red cell metabolism in positive direct coombs test after cephalothin therapy (1971) (2)
A case of paroxysmal cold haemoglobinuria with unusual serological findings. (1965) (2)
IS SEROLOGICAL POLYMORPHISM OF HUMAN DR ANTIGENS DETERMINED BY STRUCTURAL DIFFERENCES IN THE SMALLER (β) CHAIN (1979) (2)
Statistical evaluation of the determination of red cell acetylcholinesterase activity. (1970) (2)
Targeted radioimmunotherapy with B7-H3-specific 212Pb-mAb 376.96 in models of human ovarian cancer. (2016) (2)
Human lymphoblastoid cell lines as effector cells in mitogen-dependent and antibody-dependent cell-mediated lysis. (1978) (2)
Serum HLA-A and B alloantigens in patients with malignant melanoma. (1981) (2)
CSPG4 and B7-H3 as prognostic biomarkers in chordoma. (2010) (2)
Abstract 5314: Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck (2010) (2)
Modulation by cytokines of HLA antigens, intercellular adhesion molecule 1 and high molecular weight melanoma associated antigen expression and of immune lysis of clones derived from the melanoma cell line MeM 50-10 (2005) (2)
T-Cell activation by t(9;22) acute lymphoblastic leukemia-derived dendritic-like cells is associated with increased tapasin expression (2006) (2)
GLUTATHIONE IN LIVER CIRRHOSIS (1966) (2)
Uremic patients immunized with planned blood transfusions: detection of HLA antibodies with the cytotoxic test and an indirect rosette microassay. (1979) (2)
[Paroxysmal nocturnal hemoglobinuria]. (1973) (2)
High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease (2021) (2)
H-2 and ia antigens in mouse serum. Abstr. (1976) (2)
Human Leukocyte Antigen-G Is Frequently Expressed in Glioblastoma and May Be Induced inVitro by Combined 5-Aza-2-Deoxycytidine and Interferon- Treatments (2)
HLA class I antigen defects in maxillary sinus squamous cell carcinoma: potential prognostic significance☆ (2003) (2)
Heterogeneity of human peripheral blood mononuclear cells detected by monoclonal antibodies to monomorphic determinants of human Ia antigens. (1984) (2)
Coexpression of NRASQ 61 R and BRAFV 600 E in Human Melanoma Cells Activates Senescence and Increases Susceptibility to Cell-Mediated Cytotoxicity (2006) (2)
Monoclonal and polyclonal xenoantibodies to the HLA-A, B, C antigenic molecular complex do not affect the functional activity of C3 receptors. (1980) (2)
Levels of Ia-like antigen bearing lymphocytes in patients with solid primary tumors. (1981) (2)
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation (2021) (2)
Meeting report from the “ Melanoma Research : a bridge from Naples to the World . Napoli , December 5 th – 6 th 2011 ” (2012) (2)
The vitronectin receptor alpha-V beta-3, contrary to ICAM-1, is not modulated by interferon-gamma and tumour necrosis factor-alpha on melanoma cell lines. (1996) (2)
Tumor-Induced Immune Suppression and Immune Escape (2006) (2)
Cephalothin-treated normal red cells: A new type of PNH-like cells (1968) (2)
HLA Polyclonal and Monoclonal Xenoantibodies (1981) (2)
507. Chondroitin Sulfate Proteoglycan 4 (CSPG4)-Redirected T Cells Eliminate Glioblastoma-Derived Neurospheres (2016) (2)
Current Trends in Histocompatibility (1981) (2)
Therapeutic monoclonal antibodies: introduction. (2014) (2)
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells (2009) (2)
Heterogeneity of human melanoma-associated antigens defined by monoclonal antibodies and conventional xenoantisera (1982) (2)
HLA-D restriction of antigen-specific proliferative T cell responses. Inhibitory activity of antisera against HLA determinants or stimulatory antigen. (2008) (2)
[SOME OBSERVATIONS ON THE DIFFERENT HEMOLYTIC CAPACITY OF DIVERSE SERUMS TOWARD ERYTHROCYTES OF NOCTURNAL PAROXYSMAL HEMOGLOBINURIA. PRELIMINARY NOTE]. (1964) (2)
Structural Analyses of HLA-DR Antigens (1981) (2)
immune responses to viral antigens and to (2000) (2)
Enhancement of anti-tumor immunity and survival prolongation by neoadjuvant 5-FU, oxaliplatin and irinotecan (folfirinox) in pancreatic ductal adenocarcinoma patients (2018) (2)
Some red cell enzyme activities in paroxysmal nocturnal haemoglobinuria. (1966) (2)
The Major Histocompatíbility Complex in Man: Biological and Molecular Approaches (Part 1 of 2) (1976) (2)
Human High Molecular Weight Melanoma-Associated Antigen: Immunochemical Profile and Clinical Applications (1987) (2)
Corrigendum to Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers Journal of Immunological Methods, Volume 450, Year (2017), start page 73, end page 80. (2018) (2)
Expression of Intercellular Adhesion Molecule-1 ( CD 54 ) on Hematopoietic Progenitors (2003) (2)
Fab2 FRAGMENTS FROM HLA XENOANTISERA SPECIFICALLY BLOCK CYTOLYSIS MEDIATED BY HLA‐A, B ALLOANTISERA (1980) (2)
International Conference on the Biology of Melanoma. Aviano, Italy, 24-26 September 1995. (1996) (2)
Molecular profile of human melanoma associated antigens purified from spent culture medium (1979) (2)
Variability in immune infiltrates and HLA expression in cholangiocarcinoma. (2014) (2)
Differential role of HLA-A and HLA-B, C expression levels as prognostic markers in colon and rectal cancer (2022) (2)
Inhibition by Anti-HLA Class II Monoclonal Antibodies of OKT3-Induced T Cell Proliferation: Analysis of the Mechanism (1989) (2)
Serological and Structural Heterogeneity of HLA-DR and DQ Antigens in HLA-DR4 Homozygous B Lymphoid Cells (1987) (2)
Ontogeny of murine I-Ak antigens in tissue of nonlymphoid origin (2004) (2)
A solid-phase immunoassay to screen anti-HLA monoclonal antibodies. (1988) (2)
Immunochemical Characterization of a Human High Molecular Weight - Identified with Monoclonal Antibodies Melanoma Associated Antigen (1983) (2)
HLA antigens in clinical medicine and biology (1979) (2)
Diversity of anti-HLA-DR antibodies elicited by distinct anti-idiotypic monoclonal antibodies recognizing idiotopes co-expressed by the immunizing monoclonal antibody. (1992) (2)
Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial (2022) (2)
Abstract 4509: Targeting tumor-derived exosomes using a lectin affinity hemofiltration device (2020) (2)
Study of the acetylcholinesterase activity of AET-treated (2-aminoethylisothiouronium bromide) normal red cells (PNH-like cells). (1970) (2)
An immune adsorption technique for analysis of antigenic determinants reacting with HLA antisera. (1977) (2)
Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) (2020) (2)
Abstract 4017: Anti-tumor activity of a BRAF inhibitor and IFNα combination in BRAF mutant melanoma (2016) (1)
Titration calorimetry study of an anti-idiotypic antibody cascade in a human melanoma-associated antigen system. (1997) (1)
Normal human red cells treated in vitro with cephalothin. A scanning electron microscope study. (1971) (1)
Inhibition of T Lymphocyte Rosetting by HL-A Alloantisera and Complement 1 (1976) (1)
NK attack? allospecificities in leukemic cells: an escape mechanism from CTL and Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, (2011) (1)
Antiidiotypic monoclonal antibodies to anti human high molecular weight-melanoma associated antigen monoclonal antibodies (1990) (1)
Elimination of Egfr-Overexpressing Cancer Cells by CD32 Chimeric Receptor T Cells in Combination with Cetuximab or Panitumumab (2019) (1)
The major portion of rabbit antibody to serum HLA-A9 antigens is directed to allospecificity. (1978) (1)
Differential gene regulation of WT1 protein tumor antigen and the components of the antigen processing machinery by interferon-gamma signaling in myeloid leukemia (2005) (1)
Enrichment of KIR+CD57+ highly cytotoxic NK cells in sentinel lymph nodes of melanoma patients (2014) (1)
Class I and Class II HLA Antigens in Colorectal and Liver Carcinomas (1986) (1)
Procedure for the selection of HLA xenoantisera for immunochemical characterization of HLA antigens. (1977) (1)
Changes in synthesis and expression of MHC antigens induced by recombinant immune interferon (IFN-γ) in human melanoma cells (1984) (1)
Association of High Human Leukocyte Antigen B and C Expression Level with Prolonged Overall Survival in Colorectal Cancer (2018) (1)
The Effects of Anti-High Molecular Weight-Melanoma Associated Antigen (HMW-MAA) Monoclonal Antibodies (mAb) Against 11q23 Positive Acute Leukemia Cells. (2006) (1)
Melanoma chondroitin sulfate proteoglycan promotes anchorage-independent growth of melanoma cells through activation of Erk1/2 (2006) (1)
Phenotypic heterogeneity of melanoma (1988) (1)
Anti-idiotypes in melanoma. (1993) (1)
HLA Class I Antigen-Processing Machinery and HLA Class I Antigen-Derived Peptide-Complex Defects in Tumor-Cell Escape (2004) (1)
Ia antigen expression is increased on tunicamycin-resistant human B-lymphoid cells. (1984) (1)
T Cells Facilitates Identification of Tumor-Reactive Antigens Acquired by Trogocytosis Imprinting of Lymphocytes with Melanoma (2013) (1)
Glucose-Regulated Protein of 94kDa (Grp94)-Targeted Antibody-Based Combinatorial Immunotherapy for Intrahepatic Cholangiocarcinoma (2016) (1)
The SPPL3-defined glycosphingolipid repertoire regulates immune responses by improving HLA class I access (2020) (1)
Molecular analysis of anti‐idiotypic monoclonal antibodies in the HLA‐DR antigenic system (1992) (1)
Anti-CSPG4 DNA vaccination as a promising strategy for the treatment of CSPG4+ tumours: A comparative oncology trial (2019) (1)
ADCC detects a public B-cell specificity broader than DRw3 and DRw6. (1978) (1)
Activation of the Alternate Pathway of C by Human Histocompatibility (HL-A) Antibodies (1973) (1)
VACCINATION WITH HUMAN HMW-MAA DNA INDUCES A SPECIFIC ANTIBODY RESPONSE IN DOGS WITH MELANOMASIC (2009) (1)
Abnormalities of T cells isolated from mediastinal lymph nodes and peripheral blood of patients with lung carcinoma: deficit in PHA-induced expression of HLA class II antigens and in autologous mixed lymphocyte reactions (2004) (1)
Risk Prediction Model for Cisplatin-Associated Acute Kidney Injury. (2018) (1)
A novel type of soluble HLA antigens: anti-idiotypic (anti-id) mAb which bear the internal image of HLA-DQ3 antigens (1993) (1)
A radioimmunoassay and biological profile of Ia-like antigens on human melanoma cells. (1982) (1)
Antibodies in Patients with Melanoma Lymphocytes Elicited by Anti-Idiotypic Monoclonal Weight-Melanoma-Associated Antigen-Specific Cytotoxic T Fine Specificity of High Molecular (2004) (1)
Binding affinity of antigen-antibody complexes at clinically relevant hyperthermic temperatures: A proposed model (1990) (1)
Stem cells and cancer immunotherapy: Arrowhead’s 2nd annual cancer immunotherapy conference (2014) (1)
Idiotypic diversity and variable region gene usage by mouse anti-HLA-DQ3 mAb (2004) (1)
The positive direct coombs test of cephalothin-treated blood (1969) (1)
Cross-reactivity between human and murine lymphocyte antigens (1981) (1)
Ubiquitin carboxylterminal hydrolase-1: A biomarker of renal cell carcinoma and melanoma (2006) (1)
A clinically relevant mouse model of human multiple myeloma (2005) (1)
HLA-A, B, C Typing Using Serum (1984) (1)
Cross‐reacting Xenoantibodies to the Heavy Chain of H‐2 and HLA‐A, B Antigens: Serologic and Immunochemical Characterization (1980) (1)
Abnormalities in HLA class I antigen expression by melanoma cells: structural characterization and functional implications. (1993) (1)
Cultured human lymphoid cells: Tools for the biological and molecular characterization of antigens and their recognition systems (1975) (1)
Induction of Ia-like antigens by a group A streptococcal product with mitogenic activity. (1981) (1)
Cephalothin positive direct coombs test. Relationship to serum immunoglobulin concentration (1971) (1)
HLA antigen expression by melanoma cells: 43 (1993) (1)
Boronated dextran-monoclonal antibody conjugates for NCT (1985) (1)
Specific phosphorylation by calcium-EGTA complex of a 75 kDa human tumor plasma membrane protein (pp75). (1989) (1)
Monoclonal dr antibodies. Abstr. (1979) (1)
Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma (2017) (1)
Production of anti-W24 xenoantisera in rabbits. (1975) (1)
Human Ia-like antigens (1981) (1)
Immunotherapy of melanoma: peptide mimics of a human high molecular weight-melanoma associated antigen. (2000) (1)
Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC). (2018) (1)
Normal human blood treated in vitro with cephalothin. Relationship between serologic and metabolic abnormalities of red blood cells (1970) (1)
In Vivo Distribution of Anti-Human Melanoma Monoclonal Antibodies (1984) (1)
Enrichment of KIR+CD57+ highly cytotoxic NK cells in sentinel lymph nodes of melanoma patients (2014) (1)
Complement Expression on Lymphoid Cells (1978) (1)
In vivo and in vitro immunomodulatory ability of streptococcal mitogen: effects on adjuvant disease in the rat; on homograft rejection in the mouse; and on the appearance of Ia antigens on human T lymphocytes. (1985) (1)
Diversity in the fine specificity of anti-HLA-DR monoclonal antibodies elicited with syngeneic antiidiotypic monoclonal antibodies. (1991) (1)
Immunogenicity of HLA-A,B antigens expressed by human melanoma-murine fibroblast cell hybrids. (1979) (1)
Reactivity of DR xenoantisera in a cytotoxic test with human complement. (1979) (1)
Identification of monoclonal antibody defined epitopes on human leukocyte antigens utilizing phage display peptide libraries (2004) (1)
Xenoantisera to human DR antigens: Serological and immunochemical characterization (1978) (1)
Identification of monoclonal antibody defined epitopes on human leukocyte antigens utilizing phage display peptide libraries (2006) (1)
Effect of polyclonal and monoclonal HLA-DR xenoantibodies on xenogeneic mixed lymphocyte reactions (2005) (1)
[Study of some erythrocytic enzyme and metabolic activities in chronic nephropathies]. (1970) (1)
Human lymphoid cell lines as targets for DRw (1978) (1)
Structural polymorphism of the beta chain of human HLA-DR antigens. (1980) (1)
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST (2022) (1)
Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy. (2022) (1)
Rapid purification of plasmid DNA following acid precipitation of bacterial proteins. (1989) (1)
Antibody-based immunotherapy: targeting CSPG4 on human basal breast cancer stem cells. (2009) (1)
Dose-seeking and efficacy study of combination BRAFi and high-dose IFN (HDI) for therapy of advanced melanoma. (2014) (1)
β: molecular characterization and implications for immune surveillance2: molecular characterization and implications for immune surveillance-microglobulin gene mutations in human melanoma cells: molecular characterization and implications for immune surveillance (1997) (1)
LACK OF EFFECT OF CYCLOPHOSPHAMIDE ON THE IMMUNOGENICITY OF MOUSE ANTI- IDIOTYPIC MONOCLONAL ANTIBODY MK2–23 IN STAGE IV MELANOMA PATIENTS (1992) (1)
Serological and Structural Heterogeneity of HLA-DR4 Alloantigens (1984) (1)
Changes in serum ganglioside and antibody levels in soft tissue sarcoma: are they the cause or the effect of tumor progression? (2002) (1)
Radiation Enhances the Efficacy of B7-H3 Chimeric Antigen Receptor (CAR) T-Cell Based Immunotherapy for Triple Negative Breast Cancer (TNBC) (2020) (1)
Antigen Expression and Immune Lysis of Human Melanoma Cells: Analysis with Monoclonal Antibodies (1982) (1)
8th international histocompatibility workshop analysis of a goat antiserum to HLA-B15 allospecificity. (2008) (1)
Production of Anti‐W24 Xenoantisera in Rabbits1 (2008) (1)
Association of high T-cell immune infiltrate and low hemorrhage in melanoma brain metastases (MBMs) with prolonged survival. (2012) (1)
Macrophage function during the development of adjuvant disease (2005) (1)
Abstract 4390: Heat shock protein (HSP) Grp94-targeted combinatorial immunotherapy for pancreatic cancer (2012) (1)
Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research (2022) (1)
Membrane bound and cytoplasmic human melanoma associated antigens molecular and serological characterization with mono clonal antibodies (1981) (0)
Gangliosides Dendritic Cells Inhibited by Tumor-Derived Antigen-Processing Machinery in Human Restoration by IL-15 of MHC Class (2005) (0)
ICAM-1 expression is not regulated by IL-1 in human melanoma cell lines (1994) (0)
FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011” (2012) (0)
Carcinoma of the Head and Neck Cells to In Vitro Resistance of Squamous Cell Role of Antigen-Processing Machinery in the (2013) (0)
In vivo and in vitro antiinflammatory and immunoregulating properties of streptococcal mitogen: effects on adjuvant disease in the rat, on homograft rejection in the mouse, and on the appearance of Ia antigens on human T lymphocytes. (1986) (0)
Regulation of Antigen Processing Molecules in Adenovirally Engineered Human Dendritic Cells (48.10) (2007) (0)
Ralph A. Reisfeld, PhD: In Memoriam (1926–2020) (2021) (0)
I N T E R a C T I O N of H I S T O C O M P a T I B I L I T Y (2003) (0)
3.1 MHC Molecules in non-mammalian vertebrates (1989) (0)
Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) (2020) (0)
Abstract 3591: CSPG4 as innovative target for CAR redirected CIK lymphocytes against soft tissue sarcomas (2018) (0)
Monoclonal Antibodies HLA (A*0201) Mimicry by Anti-Idiotypic (1998) (0)
ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells (2017) (0)
A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma (2020) (0)
Preface (1993) (0)
Interaction of the human high molecular weight-melanoma associated antigen with the intact IgG and Fab fragments of monoclonal antibodies (1986) (0)
Coexpression of NRAS and BRAF in Human Melanoma Cells Activates Senescence and Increases Susceptibility to Cell-Mediated Cytotoxicity (2006) (0)
Stem cells and cancer immunotherapy (2014) (0)
Abstract B19: Suppression of CD8+ T-cell functions by melanoma cell-derived exosomes captured from plasma of patients with melanoma (2020) (0)
Hla xeno anti sera contain antibodies which cross react with h 2 antigens (1979) (0)
The monoclonal antibody CJA3 down-regulates the susceptibility of human tumor cell lines to natural cell-mediated cytotoxicity. (1986) (0)
Normal human red cells treated with 2-aminoethylisothiouroniumbromide (AET). Acetylcholinesterase inactivation and susceptibility to acid lysis in vitro (1966) (0)
HL Α Typing : Methodology and Clinical Aspects Volume II (2005) (0)
Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours (2018) (0)
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy) (2019) (0)
Receptor Antisense Strategies to the Type 1 Insulin-like Growth Factor Growth Inhibition of Human Melanoma Cells in Nude Mice by Updated (2006) (0)
Differential modulation by cytokines of the gene products of the HLA-D region in melanoma cells with different metastatic potential (1989) (0)
TAPASIN AND HLA CLASS I DOWN-REGULATED IN PRIMARY HUMAN MULTIPLE MYELOMA: SUITABLE INDICATOR OF POOR PROGNOSIS. B. Vélez,1 F. Grizzi,3 W. Wenhan,1 (2009) (0)
Imaging , Diagnosis , Prognosis LOH in the HLA Class I Region at 6 p 21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma (2013) (0)
Abstract LB-249: Condroitin sulfate proteoglycan 4 (CSPG4)- redirected T cells eliminate glioblastoma-derived neurospheres (2016) (0)
Biological and clinical concepts (1981) (0)
Collaboration is required for successful immunotherapy (2006) (0)
Subject Index Vol. 132, 2003 (2003) (0)
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation (2021) (0)
The identification of strong immunogenic human malignant melanoma antigen. (1992) (0)
HLA class l specific t lymphocyte clones with dual alloreactive functions (2004) (0)
MONOCLONAL ANTIBODY DEFINED MARKERS OF HUMAN MELANOMA CELLS (1987) (0)
Inhibition of Mitochondrial Fission Reverses the Immunoescape of Solid Tumors via IRE1α-XBP-1s-TPP2 axis (2020) (0)
Abstract 2439: Association of antigen processing machinery components and CD8+ T-cell infiltration in breast cancer brain metastasis (2011) (0)
Anti-idiotypic Antibodies in the HLA System (1993) (0)
Structural polymorphism of human Ia antigens recognized by the monoclonal antibody 12 and by cross-reacting I-Ek-specific alloantibodies (2004) (0)
Potential usefulness of the monoclonal antibodies to human melanoma-associated antigens (1983) (0)
[Biological and chemical aspects of histocompatibility antigens in serum]. (1976) (0)
Phosphorylated Histone H3 (PHH3) is a novel, interesting prognostic marker in GEP-NETs (2018) (0)
Multidisciplinary approaches to enhance BRAF targeted therapy in melanoma (P2092) (2013) (0)
HLA Class I Antigen Abnormalities in Tumors (2007) (0)
Anti-idiotypic monoclonal antibodies enhance the in-vitro cytotoxicity of CTL targeted to melanoma cells by Grafted chimeric receptors (1998) (0)
Novel combinatorial therapy for pancreatic adenocarcinoma (2013) (0)
Abstract 4050: Association of long term NK cell culture and TIMP3 over-expression with NK cell reduced susceptibility to leukemia and epithelial cancer cell induced damage (2015) (0)
The Major Histocompatíbility Complex in Man: Biological and Molecular Approaches (Part 2 of 2) (1976) (0)
HLA class I antigen defects in malignant cells - functional and clinical relevance (2015) (0)
Prevention of leucocyte-antibody formation. (1970) (0)
Response : Cell Line Identification (1976) (0)
Contents Volume 6 1999 (2004) (0)
HLA Class I Antigens, ß2-microglobulin, HLA Class II Antigens and Antigen Processing Molecules Expression in Uveal Melanoma: Correlation with Clinicopathological Parameters (2003) (0)
ANTIBODIES TO HUMAN Ia‐LIKE ANTIGENS AND HETEROLOGOUS ANTI‐HUMAN LYMPHOCYTE SERA (1981) (0)
Dendritic Cells from Seroma Fluids Characterization of Human Afferent Lymph (2013) (0)
Receptors for complement components and xenogeneic erythrocytes on human T- and B-lymphoid cells (1976) (0)
Xenoantisera to allospecificities of human histocompatibility antigenic systems. (1977) (0)
Differential Antigenic Profile of High Molecular Weight-Melanoma Associated Antigen (HMW-MAA) Expressed by 11q23-Positive Acute Leukemia: An Immunotherapeutic Target. (2005) (0)
Indium-111 labeled anti-melanoma monoclonal antibodies (1984) (0)
Unmasking of a primary desmoplastic melanoma tumour in the course of treatment of a metastatic disease with anti‐PD‐1 monoclonal antibody (2019) (0)
Chapter 8 HLA Anti { , { ens , Antibod . y , and Complement in the L . ymphoc . rtotoxic Reaction (0)
3.P.46 HMW-MAA AND B7H3 EXPRESSION IN HUMAN CHORDOMA (2010) (0)
MCSP-Chimeric Antigen Receptor (CAR)-Redirected T Cells Target Multiple Solid Tumors (2013) (0)
Abstract 3091: Effects of melanoma cell-derived exosomes in melanoma patients’ plasma on immune cell functions (2019) (0)
Early Hematopoietic Zinc Finger (EHZF/ZNF521) prevents tumor cell recognition by Natural Killer cells. (41.43) (2009) (0)
Effect of Anti-HLA Class I Monoclonal Antibodies on the Proliferation of T Cells Induced by PHA-P. Comparison with the Effect on T Cell Activation via the CD2 and CD3 Pathways (1988) (0)
Analysis of the antigenic profile of mucous melanoma lesions with anti-melanoma associated antigen and anti-HLA mAb: 322 (1993) (0)
Tissue characterization of components of the antigen processing machinery in pancreatic ductal adenocarcinoma (2018) (0)
Inhibiting Melanoma Cell Growth In Vitro Mimotope Induces a Humoral Response Weight Melanoma-Associated Antigen Vaccination with a Human High Molecular (2004) (0)
Molecular characterization and tissue distribution of novel. Immunogenic melanoma-associated antigens sythesized in vitro (1993) (0)
P19 08 MP – REDUCED BINDING AFFINITY OF ANTIGEN-ANTIBODY COMPLEXES AT ELEVATED TEMPERATURES (1991) (0)
ANTI-ANTI-IDIOTYPE GH1002 FAB FRAGMENT (1996) (0)
Abstract LB-431: Augmented induction of tumor antigen-specific CTL by cetuximab in head and neck cancer patients does not correlate with Fcγ receptor IIIa genotype, but relies on NK:DC cross talk mediated by interferon-γ and NKG2D (2012) (0)
Early determination of renal allograft survival: a correlation between cytotoxic antibodies in recipient sera, renal pathology, and response to antirejection therapy. (1984) (0)
Clinical Study CSPG4 as a prognostic biomarker in chordoma (2016) (0)
Recognition by CTL Carcinoma of the Head and Neck Cells to In Vitro Resistance of Squamous Cell Role of Antigen-Processing Machinery in the Soldano (2006) (0)
Response to the letter to the editors by Ottaiano et al.: “Cetuximab-dependent ADCC in cancer: dream or reality?” (2010) (0)
Effect of Interferon (IFN) and BCG on the Expression of Human Leukocyte Antigens (HLA) by Bladder Cancer Cells (1987) (0)
Potential Role of NK Cells in Progression of Intraductal Papillary Mucinous Neoplasms (IPMN) (2016) (0)
Cytotoxic antibodies to cultured human lymphoid cells in polytransfused thrombocytopenic patients: association with reduced survival of allogeneic transfused platelets. (1977) (0)
B7-H3-Specific Chimeric-Antigen Receptor T-Cell–Based Immunotherapy for Intrahepatic Cholangiocarcinoma (2018) (0)
STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients (2013) (0)
Ioannides Sequence of Antiidiotypic Antibodies ? H-terminal V 2 T-Cell Epitopes Nested in Unique NH + CD 8 Directed Expression of − Functional Idiotopes : Tumor Antigen (2005) (0)
Biotechnology in diagnostics : proceedings of the International Symposium on the Impact of Biotechnology on Diagnostics held in Rome, Italy, April 16-18, 1985 (1985) (0)
Boronated monoclonal antibody conjugates for neutron capture therapy (1986) (0)
Killer Cells Prevents Tumor Cell Recognition by Natural Early Hematopoietic Zinc Finger Protein (2009) (0)
Abstract 1574: Quantitation of HLA-A2-MAGE3271-279complexes on the DC surface improves anticancer vaccine designs (2012) (0)
Hybridomas Grown in Serum-Free Medium (1983) (0)
Abstract 569: Expression and modulation by IFN of HLA class I APM components in melanoma: Potential biomarkers of clinical response to checkpoint inhibitors (2019) (0)
Abstract 5605: Targeting cancer stem cells in squamous cell carcinoma of the head and neck with combinatorial adoptive immunotherapy (2010) (0)
The erythrocytic reduced glutathione in paroxysmal nocturnal hemoglobinuria. (1964) (0)
Hyperthermia for metastatic melanoma using monoclonal antibody-conjugated magneto-liposomes (2006) (0)
Immune Escape Mechanisms in Retinoblastoma (2004) (0)
HLA-G II GENOTYPE AND LOW LEVELS OF SOLUBLE HLA-G POST-TRANSPLANT ARE ASSOCIATED WITH FIRST YEAR REJECTION POST PEDIATRIC HEART TRANSPLANTATION.: 881 (2010) (0)
[Study of the acetylcholinesterase activity of the erythrocytes in hemolytic disease of the newborn]. (1966) (0)
O108 - Molecular analysis of the selective loss of HLA-A2 antigen expression by melanoma cells 624 MEL28 (1996) (0)
Immunotherapeutic approaches with monoclonal antibodies to immunological diseases. (1992) (0)
Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, Qatar (2021) (0)
HLA class I antigen downregulation in malignant melanoma (2002) (0)
Working Hypothesis: Elimination of Cancer Stem Cells in Solid Tumors by Immuno-Gene Therapy Using Cancer Vaccines and Created-Inhibitory RNA (2009) (0)
Interferons upregulate abnormal TAP and LMP expression in melanoma cells lines (1998) (0)
Human Histocompatibility Antigens in Malignant Tumors of Nonlymphoid Origin (1984) (0)
Abstract 4579: CSPG4 monoclonal antibodies inhibit the growth of human malignant mesothelioma (2011) (0)
190 TAPASIN AND HLA CLASS I DOWN-REGULATED IN PRIMARY HUMAN MULTIPLE MYELOMA: SUITABLE INDICATOR OF POOR PROGNOSIS. (2006) (0)
Cell growth cycle and expression of histocompatibility antigens on cultured human lymphoid cells. (1974) (0)
MHC Class I and MICA Expressions in Liver Fluke Associated Cholangiocarcinoma (2007) (0)
This information is current as Melanoma Cell Responses in a Long-Term Survivor of Sequential Immune Escape and Shifting of T Ferrone (2005) (0)
Announcements (1998) (0)
Activation ofHumanComplement byHumanLymphoid Cells Sensitized withHistocompatibili ty Alloantisera* (membrane/cytotoxic test) (1973) (0)
High frequency of HLA class I antigen processing machinery (APM) component upregulation in primary hepatocellular carcinoma tumors (2013) (0)
Antibody HC-10-Specific Peptide Chain Epitope Mimicry by Monoclonal 2-Microglobulin-Free HLA Class I Heavy β (2013) (0)
Tyrosinase reactive T cells can eliminate large established human melanoma tumors in vivo (48.23) (2011) (0)
11-OR: HLA-G II Genotype and Low Levels of sHLA-G Post-Tx are Associated With First Year Rejection in Pediatric Heart Transplantation (2010) (0)
ACTIVE SPECIFIC IMMUNOTHERAPY WITH MOUSE ANTI-IDIOTYPIC MONOCLONAL ANTIBODY MK2-23 IN PATIENTS WITH STAGE IV MELANOMA WITH NO EVIDENCE OF DISEASE. CORRELATION WITH ANTI HIGH MOLECULAR WEIGHT-MELANOMA ASSOCIATED ANTIBODIES (1993) (0)
Abstract 4726: Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell-mediated lysis of prostate and breast carcinoma cells (2016) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy) (2021) (0)
Reactivity of monoclonal antibody (mAb) GD9 with a cytoplasmic antigen preserved in formalin-fixed, paraffin-embedded gastrointestinal tumors. (1991) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) (2022) (0)
Hla xenoantisera contain antibodies which cross react with h-2 antigens. Abstr. (1979) (0)
Cation transport in normal human red cells treated with sulfhydryl compounds (1966) (0)
Monoclonal antibodies against tumor associated antigens in gastrointestinal neoplasia (1984) (0)
Monitoring of Serum HLA Class I Antigen Levels in Allogeneic Bone Marrow Transplantation (1996) (0)
APE/Ref-1 deficiency inhibits cellular transformation and metastatic potential of human melanoma cells (2017) (0)
151 Immunogenicity of chimeric (Fc portion is human) anti-idiotypic monoclonal antibody MK2-23, an internal image of human high molecular weight-melanoma associated antigen (1995) (0)
32 STAT1 regulates HLA class I upregulation and immunogenicity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients (2015) (0)
Variability in HLA-A2 antigen expression by melanoma cell lines. Functional implications (1996) (0)
Carrying the HLA-A * 0101 Allele Allele by an HLA Identical Family Member Allorecognition of an HLA-A * 01 Aberrant (2006) (0)
[Use of F (ab')2 blocking test for anti HLA antibody detection in xenoantisera]. (1980) (0)
HLA class I molecules associated with microvesicles in sera of patients with cancer induce apoptosis of activated T cells (2005) (0)
Utilization of xeno anti sera to bone marrow derived cell antigens to determine their serological and molecular properties (1977) (0)
Structural basis of tumor antigen mimicry by a mimotope isolated from a phage display peptide library (2006) (0)
Non-HLA antibodies in alloimmunized patients (1982) (0)
ADNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor. Commentary (2006) (0)
Survival rates in HLA-A2 positive patients, with stage III-IV serous adenocarcinomas of the ovary, correlates with increased expression of COX-2 and iNOS, loss of MHC Class I and II and defects of the antigen processing mechanisms at the tumour level (2008) (0)
Red cell metabolism in anaemia. The oxygen uptake in the presence of methylene blue. (1970) (0)
1430 The immunological and genomic profiling of colorectal and breast cancer cell lines can distinguish stem like from differentiated tumor cells: implications for cancer immunotherapy (2022) (0)
Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancer (2018) (0)
[Enzymatic and metabolic activities of erythrocytes in paroxysmal nocturnal hemoglobinuria]. (1970) (0)
[Problem of isoimmunization from blood transfusion in recipients of homografts]. (1970) (0)
Immunogenetic and molecular profiles (1981) (0)
Immunogenicity of murine major histocompatibility products in serum. Abstr. (1978) (0)
Humoral immunity in renal allograft recipients: Detection of non HLA lymphocytotoxic antibodies (Ab) in patients with vascular graft rejection (1980) (0)
PNH-like red cells: Mechanism of action of sulfhydryl compounds on normal red cells (1972) (0)
Issue Information (2014) (0)
Tailoring cells for clinical needs: Meeting report from the Advanced Therapy in Healthcare symposium (October 28–29 2017, Doha, Qatar) (2018) (0)
[Paroxysmal nocturnal hemoglobinuria and paroxysmal "cold" hemoglobinuria. Comparative study on the kinetics of the hemolysis]. (1968) (0)
NK cells and NK receptors (PP-007) (2010) (0)
P.04.10 PHOSPHORYLATED HISTONE H3 (PHH3) IS A NOVEL, INTERESTING PROGNOSTIC MARKER IN GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE NEOPLASMS (2018) (0)
Combinational Targeting of Prostate Carcinoma Cells and Tumors Associated Pericytes with Antibody Based Immunotherapy and Metronomic Chemotherapy (2008) (0)
Reply to Burlingham (1996) (0)
hematopoietic progenitors Expression of intercellular adhesion molecule-1 (CD54) on (2011) (0)
Abstract 2323: Inhibition of in vitro growth of human mesothelioma cells by CSPG4-specific monoclonal antibodies (2010) (0)
High frequency loss of HLA class I allospecificities in primary and metastatic melanoma lesions: 486 (1997) (0)
NKG 2 D-dependent Natural Killer Cell Cytotoxicity Different Histotypes : Analysis of Tumor Susceptibility to UL 16-Binding Protein Expression on Tumor Cell Lines of Major Histocompatibility Complex Class I-related Chain A and Updated (2002) (0)
Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (0)
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 (2015) (0)
Summary report on the second New World B-cell workshop. (2008) (0)
Association of High Tapasin Expression with Poor Prognosis in Intraductal Papillary Mucinous Neoplasms (IPMN) (2021) (0)
Melanoma and immunotherapy bridge 2015 (2016) (0)
[Action of cephalothin on the blood "in vitro": influence of some plasmatic components on the sensitivity of the erythrocytes to the drug]. (1968) (0)
Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy (2022) (0)
Differential Role of Distinct Human Leukocyte Antigen (HLA) Class I Subset Expression Levels as Prognostic Markers in Colon and Rectal Cancer: a Patient-level Pooled Analysis (2021) (0)
Abstract 1891: Tanshinone IIA is a novel agent for melanoma prevention and therapy (2010) (0)
Targeting cancer initiating cells in pancreatic adenocarcinoma (2012) (0)
HLA Typing of Cells in Long-Term Culture (2019) (0)
Polyclonal and Monoclonal Xenoantibodies to Polymorphic Determinants of Human Histocompatibility Antigens (1981) (0)
Characterization of antigen-processing machinery in human monocyte-derived immature and mature dendritic cells (2004) (0)
Red Cell Metabolism in Anaemia (1970) (0)
Active specific immunotherapy with mouse anti-idiotypic (anti-id) mAb MK2???23: 180 (1997) (0)
Differential HLA class I subunit (A, B, C heavy chain and β2-microglobulin) expression levels in normal tissues (2022) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy) (2021) (0)
148 TAP2 deficiency mediates adaptive immune evasion and immunotherapy resistance in human non-small cell lung cancer (2022) (0)
Abstract 3132: Single nucleotide polymorphisms (SNPs) in PD-L1 as predictive biomarkers for checkpoint inhibitor based-immunotherapy in caucasian patients with advanced NSCLC (2020) (0)
[Effect of 2-amino-ethylisothiouronium bromide (AET) on blood coagulation]. (1966) (0)
Issue Information (2022) (0)
Diversity of Extracellular Vesicles (EV) in Plasma of Cancer Patients (2022) (0)
[Determination of erythrocyte acetylcholinesterase by the dithiobisnitrobenzoic acid method, carried out with ready made reagents]. (1968) (0)
Structural and Functional Defects in HLA Class I Antigen Processing Machinery in Cancer Cells: Molecular Mechanisms and Clinical Relevance (2021) (0)
Human Cancer Biology SHP 2 Is Overexpressed and Inhibits pSTAT 1-Mediated APM Component Expression , T-cell Attracting Chemokine Secretion , and CTL Recognition in Head and Neck Cancer Cells (2013) (0)
Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram (2020) (0)
Abstract 2812: CSPG4-specific CAR.CIK lymphocyte-based immunotherapy to eliminate HLA class I-defective melanoma tumors (2022) (0)
Abstracts of the Conjoint Meeting of XXth International Pigment Cell Conference & Vth International Melanoma Research Congress (2017) (0)
Announcements (1998) (0)
The Antileukemic Effect of NK and NK-T Cells Against Chronic Myelogenous Leukemia Is Dominated by Interactions between Activating Molecules and Their Ligands Which Overcome Inhibitory KIR-MHC Class I Interaction. (2004) (0)
NOSC/ONR Robotics Bibliography (1961-1981). (1982) (0)
Tumor-Associated Macrophage Infiltration and Clinical Course of the Disease in Pancreatic Ductal Adenocarcinoma (2018) (0)
Identification of Chondroitin Sulfate Proteoglycan-4 In Acute Myeloid Leukemia Using Monoclonal Antibody 225.28 (2011) (0)
Abstract 4408: Prevention of post surgery tumor recurrence and metastasis of melanoma by a fully human CSPG4-specific antibody (2010) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) (2022) (0)
The Immune Milieu of Anal Squamous Cell Carcinoma: IDO Expression is Correlated with Poor Outcome (2018) (0)
[Leukocyte antigens and histocompatibility]. (1971) (0)
Molecular Genetic Analyses of Functional Melanoma-Associated Antigens (2019) (0)
Anti-idiotypic monoclonal antibodies as therapeutic vaccines. (1996) (0)
Abstract 885: Anti-CSPG4 CAR.CIK lymphocytes are effective against advanced sarcomas in 3D spheroid and xenograft models (2020) (0)
Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016 (2017) (0)
New aspects in the treatment of immunomediated diseases. (1991) (0)
Leucocyte cytotoxic isoantibodies after massive transfusion for open heart surgery. (1974) (0)
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy) (2018) (0)
T Cell Activation by t(9;22) Acute Lymphoblastic Leukemia-Derived Dendritic-Like Cells Is Associated with Increased Expression of Antigen Processing Machinery Components. (2004) (0)
Significance of the intraindividual variability of HLA IgG antibodies in renal disease patients observed with different beadsets monitored with two different secondary antibodies on a Luminex platform (2018) (0)
[Enzymatic and metabolic activities in erythrocytes in hemolytic autoimmune diseases]. (1970) (0)
Preferential selection of a subset of anti-HLA-DR monoclonal antibodies by a syngeneic antiidiotypic monoclonal antibody. (1993) (0)
Activation of the complement system by H-2 alloantisera: Differential susceptibility to lysis of thymocytes and lymphocytes (1975) (0)
Immunotherapy of Intrahepatic Cholangiocarcinoma with Fc Chimeric Receptor T-Cells (2019) (0)
Their Interaction with Cytotoxic Cells and CD 58 / CD 2 by Human Melanoma Cells and Functional Role Differential Expression of Cell Adhesion Molecules CD 54 / CD 11 a (2006) (0)
Tokuda Akihiro Tomida Shinya Toyokuni Hitoshi Tsuda Shoichiro Tsugane Tatsuhiko Tsunoda Heiichiro Udono Koji Ueda Yoshimasa Uehara Hiroo Ueno Kazuo Umezawa Toshikazu Ushijima Toshihiko Wakabayashi Kenji Wakai Tetsuro Watabe (2016) (0)
DOWN REGULATION OF TAP-1/-2 BUT NOT OF LMP-2/-7 INDICATES POOR PROGNOSIS IN PRIMARY MELANOMA (1998) (0)
Correction to: Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram (2020) (0)
Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and tumor microenvironment, overcoming multiple obstacles of CAR T therapy for solid tumors (2023) (0)
Mutation Profile of Borderline/Locally Advanced Pancreatic Ductal Adenocarcinoma Responding to Total Neoadjuvant Therapy with FOLFIRINOX (2020) (0)
A tribute to Edgardo Carosella on the occasion of the 6th International Conference on HLA-G held in Paris, France, July 9-11, 2012. (2013) (0)
Intact APM and PD-1:PD-L1 pathway upregulation in HIV-infected head and neck cancer patients. (2017) (0)
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation (2021) (0)
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (0)
[NOCTURNAL PAROXYSMAL HEMOGLOBINURIA. STUDY OF 2 CASES]. (1964) (0)
Structural Analysis of Murine and Human Ia Alloantigens (1978) (0)
MolecularHeterogeneityand Sheddingof a High-Molecular-Mass Melanoma-AssociatedAntigenIdentifiedwith MonoclonalAntibodies (2004) (0)
HLA Class II Antigen Expression in Colorectal Carcinoma Tumors as a Favorable Prognostic Marker 1 , 2 (2014) (0)
VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen (2023) (0)
Susceptibility to Immune Elimination of Epithelial and Quasi-mesenchymal Pancreatic Ductal Adenocarcinoma Cells under Basal Conditions and Following Treatment with FOLFIRINOX (2021) (0)
ICAM‐1 expression in primary melanoma lesions correlates with prognosis, but serum ICAM‐1 level does not: 152 (1993) (0)
Anti-inflammatory biologic therapies and immune surveillance of melanoma (2008) (0)
P16. Differential susceptibility of human and mouse NK cells to malignant cell-induced abnormalities in autologous combinations: a potential mechanism for the NK cell-based immunotherapy efficacy (2014) (0)
Serum B7-H3 as a Novel Prognostic Biomarker for Patients with Pancreatic Adenocarcinoma (2022) (0)
Lymphoid cell line identification and the detection of cross contamination (1980) (0)
Immunocytochemical Characterization of Gastrointestinal Neoplasia by Monoclonal Antibodies (1985) (0)
REDUCED NUMBER OF NONCYTES EXPRESSING THE INTBRACELLULAR ADHESION MOLECULL (ICAN-1) IN CHILDREN WITH CHRONIC HEPATITIS B (CUB) (1991) (0)
Expression and Characterization of Leucocyte Antigens (1984) (0)
Human Ia-like antigens (Analysis of the tissue distribution and immunochemical profile with monoclonal antibodies). (1981) (0)
Scientific Session 1 1. SMAD4 LOSS IS ASSOCIATED WITH RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH THE AUTOPHAGY INHIBITOR HYDROXYCHLOROQUINE IN PATIENTS WITH PANCREATIC ADENOCARCINOMA (2020) (0)
The Immunobiology of Malignant Melanoma (2002) (0)
Loss of LMP and TAP expression in human melanoma cells (1996) (0)
Endoplasmin antibodies and their use (2011) (0)
Presence of soluble forms of HLA class I and ICAM-1 in urine of patients with bladder tumor (1996) (0)
Cancer Therapy : Preclinical T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo (2014) (0)
Future perspectives in melanoma research (2016) (0)
In vivo andin vitro antiinflammatory and immunoregulating properties of streptococcal mitogen: Effects on adjuvant disease in the rat, on homograft rejection in the mouse, and on the appearance of Ia antigens on human T lymphocytes (2005) (0)
Differential Modulation by Anti-HLA Class I Monoclonal Antibodies of T Cell Proliferation Induced via CD2 and CD3 Pathways (1989) (0)
[Normal human erythrocytes treated with sulfhydryl compounds. Study of the kinetics of hemolysis and of the hemolytic system in relation to the erythrocytes of nocturnal paroxysmal hemoglobinuria]. (1965) (0)
Strategies to Counteract Resistance Mechanisms in CAR+ T-Cell-Based Immunotherapy for Triple-Negative Breast Cancer (2017) (0)
Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAFV600E melanoma (2015) (0)
Targeting ALDH1A1 for Immunotherapy of Cancer Stem Cells (41.20) (2009) (0)
B7-H3 Targeted CAR T Cell Immunotherapy for Primary and Metastatic/Multi-focal Intrahepatic Cholangiocarcinoma (2022) (0)
Interplay Between Checkpoint Molecule B7-H3 and Human Leucocyte Antigen (HLA) Class I Expression: Relevance to the Clinical Course of Pancreatic Ductal Adenocarcinoma (PDAC) (2021) (0)
IMMUNOGENICITY OF HLA ANTIGENS PURIFIED FROM SERUM1 (1977) (0)
Restricted Antigen - Impairs HLA Class I Organs Attracts Myeloid Dendritic Cells and IL-27 in Human Secondary Lymphoid (2014) (0)
Red cell acetylcholinesterase in ABO haemolytic disease of the newborn (1968) (0)
Association of IFN-g Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines (2011) (0)
Cell line identification. (1976) (0)
Abstract 4741: Inhibition of TNBC cell growth by CSPG4-specific mAb 225.28 with a Sonic Hedgehog pathway inhibitor (2013) (0)
Heterogenei ty in the Express ion of HLA and Tumor-assoc ia ted Antigens by Surgically Removed and Cultured Breast Carcinoma Cells (2007) (0)
Expression of HL-A Antigens on Lymphoblastoid Cells (1975) (0)
Appearance of Ia antigens on T lymphocytes stimulated by streptococcal mitogen as an in vitro model of autoimmunity. (1985) (0)
Surface antigenic structure of murine pluripotent, myeloid and erythroid stem cells. Abstr. (1979) (0)
Active Specific and Passive Immunotherapy of Melanoma: Clinical and Experimental Investigations with Murine Monoclonal Antibodies (1990) (0)
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013 (2014) (0)
Abstract 5384: Tanshinone IIA synergizes with arsenic trioxide to promote human NB4 promyelocytic leukemia cell differentiation and apoptosis (2010) (0)
Contents Vol. 132, 2003 (2003) (0)
Harnessing host innate immunity may combat acquired resistance to BRAFi (2014) (0)
Abstract 3639: Combinatorial therapy for triple negative breast cancer (2014) (0)
Abstract LB-057: Hypoxia regulation of antigen presentation machinery expression in breast cancer (2018) (0)
Defects in the Human LeukocyteAntigen Class I Antigen-Processing Machinery in Head and Neck Squamous Cell Carcinoma : Associationwith Clinical Outcome (2005) (0)
CTLA-4+ regulatory T cells are increased in cetuximab treated head and neck cancer patients, suppress NK cell cytotoxicity and correlate with poor prognosis (TUM2P.916) (2014) (0)
Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in β2 μmRNA: 38 (1993) (0)
Current trends in histocompatibility. Volume 2. Biological and clinical concepts. (1981) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Soldano Ferrone?

Soldano Ferrone is affiliated with the following schools: